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ABSTRACT

Background: For more than two decades, breast cancer researchers have
studied the benefits, risks and clinical importance of testing the receptor status
of metastatic tumors. While there is a growing consensus that the status should
be re-tested and under what circumstances that re-testing should occur, there is
little to no evidence that utilizing test results for metastatic tumor receptor status
improves the clinical outcomes of patients. In fact, there is evidence that
changes to treatment plans based on this re-testing can be harmful to patient
outcomes.
Objective: This dissertation evaluates the current state of evidence related to
altering patient treatment plans based on the re-test results of metastatic
tumors, offers an update to existing national and international standards and
executes a retrospective observational study to provide data that supports better
informed decisions on first-line metastatic treatment plans where retesting of
tumors is an option.
Methods: A thorough literature review was performed on the topic. Afterwards,
a retrospective observational study was performed at the University of
Tennessee Cancer Institute.
Conclusions: The research outcomes documented in this dissertation
demonstrate that basing first-line treatment plans for metastatic breast cancer
patients on the receptor status of the primary tumor instead of the metastatic
tumor receptor status extends the life expectancy of patients. A standard of care
is proposed that impacts national and international guidelines and reflects the
risks associated with changing the first-line treatment plans of metastatic breast
cancer patients based on the receptor status of metastatic tumors.
v

PREFACE
The Scientific Method Begins With an Observation
Amy
On January 8th, 2014 I observed Amy Adele Foster die. Three months earlier, on
our first wedding anniversary, I observed an x-ray of her lungs taken in the
Emergency Room of the LeConte Medical Center in Sevierville, TN. That x-ray
showed two liters of fluid in the pleural space of her lung. Four weeks earlier I
observed a doctor at a world renowned medical center change Amy’s medication
from one that was working to a different medication based on the fact that “her
receptor status has changed from PR- to PR+.” One week prior to the change in
medicine, I observed her primary oncologist tell her, “Good news, your tumors
are shrinking. I would estimate your life expectancy to now be four years,
instead of the one year we originally estimated.”
Allen
If the above paragraph were read backwards, one would notice that four months
after being given four years to live, my wife was dead. In the world of metastatic
breast cancer, such outcomes occasionally occur without cause; but my instincts
led me to a different conclusion. I saw correlation and wondered if it was cause
and effect. I contacted the patient advocacy group at the medical center where
her medicine was changed and asked for a scientific explanation of that decision.
It took six months to get a phone call to discuss my concerns. In those six
months, I prepared for the phone call by doing research on the topic. That
research became this dissertation.

vi

TABLE OF CONTENTS

CHAPTER 1 Introduction and General Information ............................................1
Critical Medical Decision ...............................................................................1
Breast Cancer ..............................................................................................1
Breast Cancer Staging ..............................................................................4
Receptor Status........................................................................................4
Breast Cancer Treatments.........................................................................5
Metastatic Breast Cancer ..............................................................................7
Impact.....................................................................................................8
Problem Statement ......................................................................................8
Hypothesis ................................................................................................ 10
Research Purpose ...................................................................................... 11
CHAPTER 2 Breast Cancer Literature Review .................................................. 12
Review Criteria and Process ....................................................................... 12
Permissions............................................................................................ 12
Standards ................................................................................................. 12
Advanced Breast Cancer (ABC) Standards ................................................ 13
Levels of Evidence .................................................................................. 14
NCCN Standards ..................................................................................... 14

vii

Discussion of Standards .......................................................................... 16
Retesting of Metastatic Tumor Receptors .................................................... 16
Discordance .............................................................................................. 18
How is Discordance Measured? ............................................................... 18
What Causes Discordance? ..................................................................... 19
Impact on Treatment Decisions .................................................................. 22
Clinical outcomes ....................................................................................... 24
Potential Contradictory Data ................................................................... 28
Summary of Clinical Implications ............................................................. 31
Challenges Interpreting the Literature ......................................................... 31
Progress in the Literature ........................................................................... 35
Clinical Standards Recommendation ............................................................ 37
Statistical Literature Review ....................................................................... 37
CHAPTER 3 Materials and Methods................................................................. 39
Research Purpose ...................................................................................... 39
Key Research Questions ............................................................................. 40
Hypothesis ................................................................................................ 41
Study Design ............................................................................................. 41
Discordance .............................................................................................. 42
Phenotypes and Discordance................................................................... 42

viii

Study Decision Flow ................................................................................... 44
Data Parameters ........................................................................................ 46
Variables in the Tumor Registry............................................................... 46
Variables in Electronic and Paper Charts .................................................. 47
Quality Control .......................................................................................... 47
Record Keeping ...................................................................................... 47
Confidentiality and Compliance ................................................................... 48
Statistical Considerations ............................................................................ 48
Sample Size and Power........................................................................... 48
Sample Size Discussion ........................................................................... 53
A Priori Analysis Plans ............................................................................. 54
Statistical Significance ............................................................................ 55
Statistical Methods Review ......................................................................... 56
Simulation.............................................................................................. 57
Simulation Results .................................................................................. 58
CHAPTER 4 Results and Discussion ................................................................ 67
Data Acquisition ........................................................................................ 67
Data Cleaning ........................................................................................ 67
Limited Data Set .................................................................................... 69
Finalizing the Data.................................................................................. 70

ix

Data Collection Summary ........................................................................ 72
List of Variables in the Final Dataset ........................................................ 73
Preparing the Data for Analysis ............................................................... 73
Study Results ............................................................................................ 78
Kaplan-Meier Survival Analysis ................................................................ 78
Chi-Square Analysis (RECIST Standard) ................................................... 83
Multivariate Analysis .................................................................................. 84
Complete Dataset Results ....................................................................... 85
Multivariate Results for Re-Tested Patients .............................................. 87
Univariate Statistical Analysis...................................................................... 88
Sensitivity Analysis..................................................................................... 93
CHAPTER 5 Conclusions and Recommendations .............................................. 95
Conclusion ................................................................................................ 95
Restatement of Hypothesis ..................................................................... 95
Recommendation ....................................................................................... 96
Proposed Standard of Care ..................................................................... 96
Level of Evidence ................................................................................... 97
Research Limitations .................................................................................. 97
Sample Size ........................................................................................... 97
Data Quality ........................................................................................... 98

x

Inference Space ..................................................................................... 99
Limited Ability to Examine Covariates ...................................................... 99
Researcher Bias ................................................................................... 100
Contribution ............................................................................................ 101
Future Research ...................................................................................... 102
Unanswered Question ........................................................................... 103
Definition of Discordance ...................................................................... 104
Impact .................................................................................................... 104
LIST OF REFERENCES ................................................................................. 106
APPENDIX .................................................................................................. 112
Appendix 1: List of Abbreviations .............................................................. 113
Appendix 2: Incidence Rate ...................................................................... 114
Appendix 3: Permissions .......................................................................... 115
Periodical Permissions........................................................................... 115
NCCN Permission.................................................................................. 115
Appendix 4: Operational Definitions .......................................................... 115
Appendix 5: Data Collection Sheet ............................................................ 118
Appendix 6: Data Breakdown Flowchart .................................................... 119
Appendix 7: Variables Utilized................................................................... 120
Appendix 8: Information Only Variables .................................................... 124

xi

Appendix 9: Discordant Patient Variables .................................................. 126
Appendix 10: Initial Cox Regression Results .............................................. 127
Appendix 11: Power Tables ...................................................................... 128
Appendix 12: Simulation Definitions .......................................................... 141
Appendix 13: Table of MATLAB Programs .................................................. 143
Appendix 14: MATLAB Program 1 ............................................................. 144
Appendix 15: MATLAB Program 2 ............................................................. 146
Appendix 16: MATLAB Program 3 ............................................................. 148
Appendix 17: MATLAB Program 4 ............................................................. 150
Appendix 18: MATLAB Program 5 ............................................................. 151
Appendix 19: MATLAB Program 6 ............................................................. 151
Appendix 20: MATLAB Program 7 ............................................................. 153
Appendix 21: MATLAB Program 8 ............................................................. 159
VITA .......................................................................................................... 165

xii

LIST OF TABLES

Table 1. Breast Cancer Staging ........................................................................4
Table 2. ABC2 Relevant Standards ................................................................. 13
Table 3. ABC2 Levels of Evidence ................................................................... 15
Table 4. Receptor Discordance Rates ............................................................. 18
Table 5. Receptor Combinations.................................................................... 19
Table 6. Change in Treatment Plans ............................................................... 22
Table 7. Receptor Phenotypes ....................................................................... 43
Table 8. Phenotype Treatments ..................................................................... 43
Table 9. Literature Survival Data .................................................................... 50
Table 10. Power Table for L3.5 C0 C .01 ........................................................ 60
Table 11. Power Table for L3.5 C0 C .05 ........................................................ 60
Table 12. Power Table for L3.5 C0 B10 .05 ..................................................... 61
Table 13. Power Table for L3.5 C0 B2 .05 ....................................................... 62
Table 14. Power Table for L3.5 C50 C .05 ...................................................... 64
Table 15. Power Table for L3.5 C0 C N85/15 .05 ............................................. 65
Table 16. Key Data File Names ...................................................................... 67
Table 17. Data Collection Files ....................................................................... 70
Table 18. Sample Size Completeness.............................................................. 74

xiii

Table 19. Sensitivity Analysis Records ............................................................ 75
Table 20. Sample Size Examples .................................................................... 77
Table 21. Univariate Analysis ......................................................................... 89
Table 22. Appendix 1- List of Abbreviations .................................................. 113
Table 23. Appendix - Seer Breast Cancer Incidence Rates ............................. 114
Table 24. List of Variables Utilized ................................................................ 120
Table 25. Information Variables ................................................................... 124
Table 26. Discordant Patients Variables ........................................................ 126
Table 27. L3.5 C0 C .01 ............................................................................... 129
Table 28. L3.5 C0 C .05 ............................................................................... 129
Table 29. L3.5 C0 B10 .01 ........................................................................... 130
Table 30. L3.5 C0 B10 .05 ........................................................................... 130
Table 31. L3.5 C0 B5 .01 ............................................................................. 131
Table 32. L3.5 C0 B5 .05 ............................................................................. 131
Table 33. L3.5 C0 B2 .01 ............................................................................. 132
Table 34. L3.5 C0 B2 .05 ............................................................................. 132
Table 35. L2.0 C0 C .01 ............................................................................... 133
Table 36. L2.0 C0 C .05 ............................................................................... 133
Table 37. L5.0 C0 C .01 ............................................................................... 134
Table 38. L5.0 C0 C .05 ............................................................................... 134

xiv

Table 39. L3.5 C25 C .01 ............................................................................. 135
Table 40. L3.5 C25 C .05 ............................................................................. 135
Table 41. L3.5 C25 B10 .01 ......................................................................... 136
Table 42. L3.5 C25 B10 .05 ......................................................................... 136
Table 43. L3.5 C50 C .01 ............................................................................. 137
Table 44. L3.5 C50 C .05 ............................................................................. 137
Table 45. L3.5 C50 B10 .01 ......................................................................... 138
Table 46. L3.5 C50 B10 .05 ......................................................................... 138
Table 47. L3.5 C0 C N70/30 .01 ................................................................... 139
Table 48. L3.5 C0 C N70/30 .05 ................................................................... 139
Table 49. L3.5 C0 C N85/15 .01 ................................................................... 140
Table 50. L3.5 C0 C N85/15 .05 ................................................................... 140
Table 51. MATLAB Programs Descriptions ..................................................... 143

xv

LIST OF FIGURES

Figure 1. Breast Cancer Incidence Rates ...........................................................3
Figure 2. Breast Cancer Mortality Rates ............................................................3
Figure 3. Liedtke Discordance Results (p. 1956) .............................................. 25
Figure 4. Niikura Discordance Results (p. 597) ................................................ 26
Figure 5. Karlsson (p. 6) ................................................................................ 27
Figure 6. Chang (p. 597) ............................................................................... 28
Figure 7. Amir, Miller (p. 591) ........................................................................ 29
Figure 8. Wilking Survival Curves (p. 558) ...................................................... 32
Figure 9. Wilking Data Flowchart (p. 556) ....................................................... 34
Figure 10. Study Decision Flow ...................................................................... 44
Figure 11. Null Survival Curve ........................................................................ 50
Figure 12. Null and Alternative Curves ............................................................ 51
Figure 13. SAS Power Curves ......................................................................... 52
Figure 14. JMP Power Calculation ................................................................... 53
Figure 15. Simulation Flow ............................................................................ 59
Figure 16. Actual Sample Sizes ...................................................................... 72
Figure 17. Overall Survival Curve ................................................................... 79
Figure 18. Re-test versus Not Re-tested Survival Curve ................................... 80

xvi

Figure 19. Concordant versus Discordant Survival Curves ................................ 81
Figure 20. Metastatic Versus Primary.............................................................. 82
Figure 21. RECIST Chi Square Analysis ........................................................... 83
Figure 22. Whole Dataset Final Results ........................................................... 85
Figure 23. pPheno KM Analysis ...................................................................... 86
Figure 24. Multivariate Results for Re-Tested Patients ..................................... 87
Figure 25. Visceral versus Non-Visceral .......................................................... 90
Figure 26. Cox Regression with Visceral.......................................................... 91
Figure 27. Visceral Patients Only .................................................................... 92
Figure 28. Best Case Curves .......................................................................... 93
Figure 29. Worst Case Curves ........................................................................ 94
Figure 30. Periodical Permissions ................................................................. 115
Figure 31. Data Collection Sheet .................................................................. 118
Figure 32. Data Breakdown Flowchart .......................................................... 119
Figure 33. Initial Complete Cox Regression ................................................... 127

xvii

CHAPTER 1
INTRODUCTION AND GENERAL INFORMATION

Critical Medical Decision

This research endeavor focuses on a medical decision. This decision is one that
oncologists and breast cancer patients must make together regarding
appropriate treatment plans upon the recurrence of metastatic breast cancer.
Currently, there is no clear evidence based protocol that indicates how to
determine the best first-line treatment plan after recurrence when a certain set
of circumstances exist. These circumstances involve the discordance between
protein receptors of the primary and metastatic tumors. The purpose of this
research was to collect and analyze the data that would produce a definitive
treatment protocol. To understand the complex nature of determining the
appropriate treatment plan, it is important to understand some basic facts about
breast cancer. A list of abbreviations is found in Appendix 1.

Breast Cancer

The American Cancer Society defines breast cancer as:
A malignant tumor that starts in the cells of the breast. A malignant tumor
is a group of cancer cells that can grow into (invade) surrounding tissues
or spread (metastasize) to distant areas of the body. The disease occurs
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almost entirely in women, but men can get it, too ("Breast Cancer," 2015,
p. 2).
This dissertation’s focus was exclusively on breast cancer in women. Breast
cancer generally develops in the milk ducts (ductal carcinoma) or the milk
producing lobules (lobular carcinoma). Other, less frequent types of breast
cancer also exist. Breast cancer is detected in several ways, ranging from
mammography or other imaging technology, self-breast exams, or doctor’s
physical exams. Any of these methods may detect a potential tumor. Once a
tumor is suspected, a biopsy is generally performed to determine whether the
tumor actually exists and whether it is cancerous. In some cases, no tumor is
found. In other cases, the tumor is benign (non-cancerous). In the remaining
cases, breast cancer is diagnosed ("Breast Cancer," 2015).
Breast cancer is the most common form of cancer for women in the United
States. A woman born today in the U.S. has a 1 in 8 lifetime risk of being
diagnosed with breast cancer. In 2015, an estimated 232,000 case of breast
cancer will be diagnosed in the U.S., affecting approximately 1,000 women, and
a few men, per working day. It is likewise estimated that 40,000 women will die
from breast cancer, actually metastatic breast cancer, this year ("Breast Cancer,"
2015, pp. 9-10). Approximately 60,000 cases of non-invasive Stage 0 breast
cancer, sometimes called pre-cancer, will also be diagnosed each year as well.
These particular cases are not included in most incidence statistics because no
medical consensus exists that Stage 0 is cancer or whether it will eventually
transform into invasive cancer ("Breast Cancer," 2015).
Breast cancer trends can be somewhat difficult to estimate. Arguments among
experts on measurement techniques and the impact of increased mammography
testing can cloud the discussion. Figures 1 and 2 illustrate breast cancer trends
since 1975. The data were obtained from the SEER database and are listed in
2

Figure 1. Breast Cancer Incidence Rates

Figure 2. Breast Cancer Mortality Rates
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Appendix 2 (Howlader N, 2015). Overall, the incidence rate of breast cancer in
the United States has been increasing since 1975, with a peak in 1999 and a
slight decline over the last ten years. The death rate peaked in 1989 at 33.23
deaths per 100,000 women. This rate has been decreasing for the last twenty
five years, primarily due to early detection and chemotherapy (Berry et al., 2005;
Howlader N, 2015). In 2011, the death rate reached a recent low of 21.5 deaths
per 100,000 women in.
Breast Cancer Staging
Breast cancer is staged using the common Stage 0 – 4 scale which is
summarized in Table 1 ("Breast Cancer," 2015, p. 42).

Table 1. Breast Cancer Staging

Stage
0
1
2
3

4

Description
Carcinoma In Situ. The cancer is in the original cell structure and has
not invaded into nearby tissue. Considered “pre-cancer”.
These cancer is still relatively small and either have not spread to the
lymph nodes or have a tiny area of cancer spread in the sentinel lymph
node.
These cancer is larger and/or have spread to a few nearby lymph nodes.
The tumor must be large (greater than 5 cm or about 2 inches across)
or growing into nearby tissues (the skin over the breast or the muscle
underneath), or the cancer has spread to nearby lymph nodes.
These cancer has spread beyond the breast and lymph nodes (at
original diagnosis) to other parts of the body. Breast cancer most
commonly spreads to the bones, liver, brain and lung.

Receptor Status.
A key diagnostic characteristic of breast cancer is determining the receptor status
of the tumor ("Breast Cancer," 2015, p. 35). Receptors are proteins in or on
human cells that promote the attachment of other proteins to the cell that fuel
4

growth. Two types of receptors that are of interest in breast cancer are
progesterone (PR) and estrogen (ER). When present, these receptors, promote
cancer cell growth by utilizing the naturally occurring hormones in a woman’s
body. If these receptors are present, the tumor is termed ER+ (ER positive)
and/or PR+ (PR positive). The absence of these receptors are termed ER- and
PR-, respectively. Another protein of interest is HER2 (human epidermal growth
factor receptor 2), also referred to as HER2/neu. If this protein is overexpressed
in a tumor, that tumor is termed HER2+, otherwise it is termed HER2- ("Breast
Cancer," 2015, pp. 35-36).
When a women is first diagnosed with breast cancer, the tumor, referred to as
the primary tumor, is tested to determine its receptor status. The receptor status
is one aspect of the patient’s diagnosis utilized to determine an appropriate
treatment plan. If a patient’s breast cancer recurs as a metastatic tumor(s), it is
now generally accepted practice to test the metastatic tumor’s receptor status.
When the metastatic tumor is tested (often referred to as re-tested in the
literature), the metastatic tumor receptors are compared with the primary tumor
receptor status. When the assessment of the primary tumor receptor status and
metastatic tumor receptor status yield the same result, the tumor statuses are
deemed concordant; when the results differ, the tumor statuses are deemed
discordant.
Breast Cancer Treatments
Breast cancer is treated in a variety of ways. The determination of a treatment
plan for a particular patient is based on the stage of the cancer at diagnosis and
other physical and histological characteristics of the tumor. A comprehensive list
of breast cancer treatments are outlined by the American Cancer Society and
include those listed below ("Breast Cancer," 2015, pp. 49-92).
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Breast Surgery. A lumpectomy can remove smaller tumors and conserves a
majority of the breast, leaving a scar and some change in breast shape. The
complete removal of the breast by a mastectomy may be required based on the
size of the tumor or other complications. Occasionally, a patient chooses a
prophylactic mastectomy (single or double) in order to lessen the risk of a
recurrence of cancer in the breast. These options will often lead to some sort of
elective reconstructive surgery (pp. 51-55).

Lymph Node Surgery. Lymph node surgery is performed to determine if the
breast cancer has spread beyond the breast to lymph nodes underneath the
armpit. One or more of these lymph nodes may be removed for evaluation. The
presence of cancer cells in the lymph nodes indicates a higher probability that
the breast cancer has spread to the bloodstream and thus to other locations in
the body, such has the liver, lungs or brain. The more prevalent the cancer is in
the lymph nodes, the more likely the patient will be prescribed chemotherapy as
an adjuvant therapy ("Breast Cancer," 2015, pp. 57-59).

Radiation. Radiation therapy is used to destroy cancer cells with high-energy
rays. Radiation is often administered to the breast and clavicle area after a
lumpectomy and sometimes after a mastectomy to the breast and clavicle area
to increase the probability that any unknown, but remaining cancer cells are
destroyed (pp. 64–67).

Chemotherapy. Chemotherapy (chemo) is referred to as a systemic treatment.
Systemic is a type of therapy that does not attack a known, specific cancer cell
or tumor; rather it is utilized to reach cells throughout the body when cancer is
known or suspected to have spread. Chemo is used in an attempt to kill cancer
cells that may have spread from the breast, beyond the lymph nodes, to other
areas of the body. Adjuvant chemotherapy is the precautionary use of chemo
where there is no evidence the cancer has spread; however there exists a
concern that it has spread, a decision that is generally based on the analysis of a
6

patient’s lymph nodes (pp. 68-70).

Hormonal Therapy. Hormone therapy is another form of systemic therapy. It is
most often used as an adjuvant therapy to help reduce the risk of the cancer
recurrence after surgery if the patient is hormone receptor-positive. It is also
used to treat cancer that has returned after the initial treatment. Approximately
2 out of 3 breast cancers are hormone receptor-positive. These cancers contain
receptors for the hormones estrogen (ER+ cancers) and/or progesterone (PR+
cancers). Hormone therapy for breast cancer either lowers hormone levels or
prevents hormones from assisting breast cancer cell growth. A woman's ovaries
are the main source of estrogen until menopause. After menopause, smaller
amounts of estrogen are still made in the body's fat tissue. Estrogen promotes
the growth of cancers that are hormone receptor-positive. ("Breast Cancer,"
2015, pp. 73-74). Tamoxifen is a common drug prescribed for hormone positive
patients. Femara is a common drug prescribed for hormone positive, postmenopausal women.

Targeted Therapy. This terminology is used to describe systemic therapy for
HER2+ patients. Herceptin (trastuzumab) is a common drug prescribed to breast
cancer patients with HER/neu positive tumors (pp. 77-79).

Metastatic Breast Cancer

Metastatic breast cancer (MBC) is defined as breast cancer that has spread
beyond the breast. If this spreading is observed when the breast cancer is first
discovered, the cancer will be termed Stage 4. Traditionally, if the cancer recurs
after the initial discovery and treatments, then it is typically referred to as
recurrent metastatic breast cancer. Metastatic breast cancer has no cure. A
person diagnosed with MBC will most likely die of MBC. The median life
7

expectancy of people diagnosed with MBC is between 2-3 years (Dawood,
Broglio, Buzdar, Hortobagyi, & Giordano, 2010). Metastatic breast cancer is
further defined by its location. If the cancer is confined to lymph nodes in the
area of the breast, it is called regional. Otherwise, if it has spread to other
organs, it is called distant. The statistic cited earlier that approximately 40,000
woman (and a few men) die annually from breast cancer is somewhat
misleading. It is more accurate to state that yearly 40,000 people will die of

metastatic breast cancer. In general, people do not die from cancer in the
breast; they die when it has spread to other organs, thus metastatic breast
cancer.
Impact
Currently, national databases do not track the number of women who are
diagnosed with metastatic breast cancer. Given the constant mortality rate of
approximately 40,000 women per year dying of MBC ("Breast Cancer," 2015), by
extension, for each woman who dies another woman will be told she has
metastatic breast cancer. Based on this logic, I estimate 40,000 U.S. women are
diagnosed with metastatic breast cancer each year.

Problem Statement

For more than two decades, breast cancer researchers have studied the benefits,
risks and clinical importance of testing the receptor status of metastatic breast
cancer tumors. While a growing consensus exists that encourages re-testing of
the metastatic receptor status, and the circumstances under which re-testing
should occur, there is little to no evidence that changing first-line treatment
plans based on the metastatic tumor status improves clinical outcomes. In fact,
8

there is evidence that changes to first-line treatment plans based on the retested tumor receptor status can indeed harm patient outcomes. The first-line
treatment plan is the first treatment after diagnosis of metastatic breast cancer.
It is common for MBC patients to cycle through many treatment plans over time
as each treatment will eventually become ineffective. While extensive research
on this topic exists, the most important question has yet to be addressed:

Does basing a patient’s first-line treatment plan on the receptor status of
metastatic tumors, when discordant with the receptor status of the primary
tumor, improve patient outcomes?
The above critical question has not been directly or adequately addressed in the
literature. In Chapter 2, I review the research related to this question and
summarize both the research results and generally accepted practices that have
evolved in the medical literature. I also propose an answer to my key question
based on the literature review, and subsequently substantiate that answer with
the data analysis provided in this dissertation.
The essence of this dissertation centers on the key decision that doctors and
patients must make when all of the following conditions exist:
1. Metastatic breast cancer has recurred (this excludes an initial stage 4
diagnosis).
2. The metastatic cancer has been biopsied.
3. The receptor status of the metastatic tumor has been determined.
4. The receptor status of the metastatic tumor is discordant from that of the
primary tumor.
5. The first-line treatment plan is being determined.

9

When all the above conditions occur, the oncologist and patient must make the
following decision:

Should the first-line treatment plan be based on the receptor status of the
primary tumor or on the receptor status of the metastatic tumor?
Currently, there is insufficient research based evidence to inform clear guidelines
for national and international standards where discordance exists. The vague
standards that do exist are discussed in the literature review section. I estimate
6,000 U.S. women a year are diagnosed with discordant receptor results and,
along with their physicians, must decide among conflicting treatment plans
indicated by the discordance. This estimate is based on my prior estimate that
U.S. 40,000 women are diagnosed yearly with metastatic breast cancer and the
15% of those cases that I found in my data to be discordant. Around 521,900
people die of breast cancer each year world-wide ("Global Cancer Facts &
Figures," 2012, p. 37). Using a conservative ratio of 10:1, I also estimate 60,000
women a year world-wide will have discordant receptor statuses and be faced
with the decision investigated by this dissertation.

Hypothesis

Based on a thorough review of the literature, I hypothesized that:

In discordant cases, if the first-line treatment plan is based on the receptor
status of the primary tumor, the median life expectancy of MBC patients will be
longer than MBC patients whose first-line treatment plan is based on the
receptor status of the metastatic tumor.

10

Research Purpose

The purpose of this dissertation was to determine the impact on patient

outcomes in recurrent metastatic breast cancer diagnoses with discordant
receptors when the first-line treatment plan is based on the receptor status of
metastatic tumor(s) instead of the receptor status of the primary tumor(s). My
ultimate goal is that the results of this dissertation leads to changes in
international and national standards regarding the determination of first-line
treatment plans in discordant cases of metastatic breast cancer, and to provide a
higher level of evidence for those standards.

11

CHAPTER 2
Breast Cancer Literature Review

Review Criteria and Process

I conducted a thorough literature review on research related to metastatic breast
cancer tumor retesting published prior to November 2014. Key phrases such as
“metastatic receptor status,” “metastatic receptor test,” “discordance” and
“hormone receptor” were queried during the electronic literature search.
Searches for more recent and most cited publications were performed. The
purpose of this critical literature review was to a) summarize the current data
related to the risks and benefits of changing treatment plans based on metastatic
tumor receptor status, b) assess the efficacy of the current clinical standards for
assessing and utilizing metastatic tumor receptor status, and c) provide the data
necessary to form my hypothesis.
Permissions
Permissions were obtained for all cited figures and extended quotes. Permission
information is contained in Appendix 3.

Standards

Two medical standards organizations informed my research, the Advance Breast
Cancer International Conference (Cardoso et al., 2012; Cardoso et al., 2014),
and the National Comprehensive Cancer Network® (NCCN.org, 2014).
12

These organizations provide physicians with care standards recommendations
based on the best available evidence. These standards often inform the clinical
practice guidelines for medical facilities. Each standards organization has a
defined level of evidence (LoE) scale to support and add context to their
recommendations. As stated in Chapter 1, the goal of this dissertation is to
impact the standards relevant to my hypothesis provided by these organizations.
Advanced Breast Cancer (ABC) Standards
“The ABC Consensus Conference was created by the European School of
Oncology (ESO) with the ambitious goal of improving outcomes for all patients
with ABC” (Cardoso et al., 2014, p. 1). This organization first met in 2011,
resulting in ABC1 standards (Cardoso et al., 2012). The conference met again in
2013 (ABC2) and updated the standards (Cardoso et al., 2014). These standards
focus specifically on patients with metastatic breast cancer. The current ABC2
standards (Cardoso et al., 2014, pp. 10-11) that are relevant to my research are
found in Tables 2.

Table 2. ABC2 Relevant Standards

Guideline
A biopsy (preferably providing histology) of a metastatic lesion
should be performed, if easily accessible, to confirm diagnosis
particularly when metastasis is diagnosed for the first time
Biological markers (especially HR and HER-2) should be reassessed
at least once in the metastatic setting, if clinically feasible.
If the results of tumour (sic) biology in the metastatic lesion differ
from the primary tumour (sic), it is currently unknown [emphasis
mine] which result should be used for treatment-decision making.
Since a clinical trial addressing this issue is difficult to
undertake [emphasis mine], we recommend considering
[emphasis mine] the use of targeted therapy (ET and/or anti HER-2
therapy) when receptors are positive in at least one biopsy,
regardless of timing.
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LoE
1C

2C
Expert
Opinion

Levels of Evidence
The relevant levels of evidence definitions used by ABC2 are listed in Table 3
(Cardoso et al., 2014). The levels of evidence definitions utilized by the ABC
conference were originally published by Guyatt et al. (2006). The meaning of

expert opinion was not defined in the literature I reviewed. I therefore inferred
that expert opinion equates to no evidence available as defined by the LoE
criteria, and the recommended standard is based solely on the clinical opinions of
those assembled to reach consensus. On most guidelines where a level of
evidence was defined, cited references supported the guideline. No references
were cited to support the guideline listed as expert opinion in Table 2.
NCCN Standards
The National Comprehensive Cancer Network® (NCCN) is a not-for-profit
organization consisting of 26 of the world's leading cancer centers. NCCN creates
clinical practice guidelines for clinicians and healthcare professionals (NCCN.org).
All NCCN guidelines I reference are reported at a 2A level of evidence, unless
otherwise noted. NCCN defines a 2A level of evidence as one with a lower-level
evidence, with uniform NCCN consensus that the intervention is appropriate
(NCCN.org, 2014, p. MS1).
The relevant NCCN guidelines state:
The NCCN Panel recommends that metastatic disease at presentation or
first recurrence of disease should be biopsied as part of the workup for
patients with recurrent or stage IV disease. This ensures accurate
determination of metastatic/recurrent disease and tumor histology, and
allows for biomarker determination and selection of appropriate
treatment.

14

Table 3. ABC2 Levels of Evidence

LoE

Quality of Supporting
Evidence

Implications

1A

Randomized Clinical Trials (RCTs)
without important limitations or
overwhelming evidence from
observational studies

Strong recommendation,
can apply to most patients
in most circumstances
without reservation

1B

RCTs with important limitations or
exceptionally strong evidence
from observational studies

Strong recommendation,
can apply to most patients
in most circumstances
without reservation

1C

Observational studies or case
studies

Strong recommendation,
but may change when
higher quality of evidence
becomes available

2A

Randomized Clinical Trials (RCTs)
without important limitations or
overwhelming evidence from
observational studies

2B

RCTs with important limitations or
exceptionally strong evidence
from observational studies

Weak recommendation,
best action may differ
depending on
circumstances or patients’
or societal values
Weak recommendation,
best action may differ
depending on
circumstances or patients’
or societal values

2C

Observational studies or case
studies

Very weak
recommendation, other
alternatives may be equally
reasonable

Expert

No Evidence, just the best guess
of those on the committee

Data is needed

Opinion

(This is my definition based on
researching the designation)
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Determination of hormone receptor status (ER and PR) and HER2 status
should be repeated in all cases when diagnostic tissue is obtained. ER and
PR assays may be falsely negative or falsely positive, and there may be
discordance between the primary and metastatic tumors…
The NCCN Panel recommends that re-testing the receptor status of
recurrent disease be performed, especially in cases when it was previously
unknown, originally negative, or not overexpressed. For patients with
clinical courses consistent with hormone receptor-positive breast cancer,
or with prior positive hormone receptor results, the panel has noted that a
course of endocrine therapy is reasonable, regardless of whether the
receptor assay is repeated or the result of the most recent hormone
receptor assay (NCCN.org, 2014, p. MS45).
Discussion of Standards
The level of evidence relating to a first-line treatment plan choice for MBC
patients with discordant receptor results is insufficient, and lacks citations to
literature to support decision making. ABC2 states the level of evidence is expert
opinion. The NCCN standard states the level of evidence is 2A; however there
are no citations supporting that recommendation. These standards also contain
weak language such as reasonable, currently unknown, and recommend

considering. Further research is needed to better inform standards, and to
improve patient outcomes related to treatment decisions.

Retesting of Metastatic Tumor Receptors

Numerous papers have been published addressing the question of whether
metastatic tumors should be biopsied and tested for receptor status
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determinations. The overwhelming consensus in the literature points to retesting and is best summarized as follows:
While biopsy of the metastatic site may not be prospectively able to
demonstrate improved outcome for each patient – at least for the time
being – it is paramount to introduce a culture of systematically biopsying
(sic) metastases in order to gain information on the biology of the disease
and, accordingly, select the best treatment option for our patients
(Criscitiello et al., 2014, p. 6).
One of the key reasons re-testing has become more prevalent is the use of fine
needle aspiration (FNA) which makes biopsies of smaller tumors more accessible
and less painful to patients (Foukakis, Astrom, Lindstrom, Hatschek, & Bergh,
2012). Routine FNA, coupled with researchers’ desire for more robust clinical
data, has recently led to protocol revisions by ABC2 and NCCN that include
recommendations for performing biopsies and comparing primary and metastatic
tumors’ receptor statuses. Until such metastatic biopsies became common, MBC
patients’ first-line treatment plans were based on the receptor status of the
primary tumor, since the metastatic tumor status was not able to be assessed
without the biopsy.
Criscitiello et al. (2014), provides an instructive review of the benefits, risks, and
the how and when to biopsy metastatic tumors. These topics are also well
covered by Foukakis et al. (2012). Articles by Penault-Llorca et al. (2013) and
Turner and Di Leo (2013) provide excellent decision flowcharts for making biopsy
and treatment determinations. Based on the weight of the evidence, biopsies of
the metastatic tumor(s) and re-testing the receptor status has become standard
practice. The NCCN guideline on re-testing metastatic tumors recommends “that
metastatic disease … be biopsied … This … allows for biomarker determination
and selection of appropriate treatment” (Carlson et al., 2012, p. 3). As a
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consequence of following the NCCN or ABC2 standards on re-testing, the
determination of the proper treatment plan to prescribe when the receptor status
of the metastatic tumor and the primary tumor are discordant is a common
conundrum in current clinical practice.

Discordance
Many researchers study the percentage of discordance between the receptor
status of the primary tumor and the metastatic tumor (Amir, Clemons, et al.,
2012; Aurilio et al., 2014; Dieci et al., 2012; Farolfi, Ibrahim, Scarpi, & Amadori,
2013; Niikura et al., 2012). A recent meta-analysis by Aurilio et al. (2014)
summarizes 48 articles totaling 3,000 – 4,000 tumors. Table 4 shows the pooled
discordance rate found in that article.

Table 4. Receptor Discordance Rates

Receptor
ER
PR
HER2

Discordance
20%
33%
8%

How is Discordance Measured?
A cancer tumor contains three receptors of interest, and each can be positive or
negative, thus there are eight (23) total combinations. In the literature, most
authors call a difference in any receptor status, primary versus metastatic, a
discordance. Thus, a change from one of the possible eight combinations to one
of the remaining seven combinations, is considered a discordance There are 56
(8x7) such discordances. However, not all of those discordances would dictate a
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treatment change. For example, if a patient’s receptor status is ER+, PR+ and
HER2- in their primary tumor and ER+, PR-, HER2- in their metastatic tumor, the
treatment plan will be the same, since the ER+ status indicates the same
treatment for either set of results. Thus, not all discordances are clinically
important for determining treatment plans. However, very few authors delineate
between the possible discordant patterns. The receptor combinations and their
corresponding descriptions are listed in Table 5. Clearly and strictly defining
discordance and its impact on treatment plans is an important issue in this
research, and a weakness in the current literature.

Table 5. Receptor Combinations

Receptor Combination

Description

ER-, PR-, HER2-

Triple Negative (TNBC)

ER+, PR+, HER2-

Hormone Receptor Positive (HR+)

ER+, PR-, HER2-

ER positive, PR negative (HR+)

ER-, PR+, HER2-

ER negative, PR positive (HR+)

ER-, PR-, HER2+

HER2 Positive, HR- (HER2+)

ER+, PR+, HER2+

Positive Breast Cancer (PBC)

ER-, PR+, HER2+

HR positive, HER2 positive (PBC)

ER+, PR-, HER2+

HR positive, HER2 positive (PBC)

What Causes Discordance?
Ultimately, it may or may not be important to understand the causes of
discordance. Some theories in the literature as to the causes of discordance are
outlined in this section for completeness. However, for my particular research,
the cause of discordance is not considered. My research interest lies in whether
there is discordance, not why, and whether that discordance leads to altered
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patient treatment plans, and whether those altered plans lead to better or worse
clinical outcomes.
One of the most common reasons proposed for discordance is the possibility of
measurement error. That is, the two tumor receptor status results differ not
because the tumors are different, rather there exists variation (inaccuracy) in the
measurement process itself. The primary tumor can usually be measured based
on the extraction of the full tumor. The metastatic tumor is measured on the
basis of a FNA biopsy, given that a metastatic tumor can rarely be removed. A
tendency in the literature is to assume the metastatic receptor status
measurement is subject to more error (Foukakis et al., 2012).
Sighoko, Liu, Hou, Gustafson, and Huo (2014), use Bayesian methods to extract
measurement error in order to estimate the true discordance rates. Their study
provides some insight into the question of what percent of discordance may be
due to measurement error. Liedtke et al. (2009), is an excellent example of a
study where measurement error is contemplated as a key cause of discordance.
The authors state:
We hypothesize that the poor survival outcome of patients with discordant
receptor results may be due to both false-negative results that could lead
to withholding endocrine therapy (or trastuzumab) and false-positive
receptor results may also contribute some by leading to an initial period of
ineffective therapy with targeted agents in patients who do not benefit.
…mistakes in receptor determination can lead to suboptimal therapy.
...our results illustrate the need to increase standardization and
implementation of guidelines for hormone and HER2 receptor
determination” (p. 1957).
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There is not a consensus in the literature on the percentage of discordance that
is due to true biological difference and the percentage due to measurement
error. Based on the data I evaluated, I estimate that measurement error
accounts for 33% to 50% of discordances. This range is a qualitative estimate
only; thus it is not possible to put statistical confidence on the estimate.
Discussions about other causes of discordance are less conclusive. A good
example of other hypothesized reasons for discordance is found in Dieci et al.
(2012) where they indicate that in addition to measurement errors, the
heterogeneity of cancer tumors and the impact of previous treatments could also
be reasonable explanations for a change in receptor status (p. 4).
Foukakis et al. (2012) also outlines the potential causes of discordance:
However, the reason for this discrepancy is less clear and both technical
and biological explanations have been discussed. The use of various
methods for ER (biochemical versus IHC assays) and HER2 (IHC versus
FISH), the variability caused by sampling methods (fine-needle aspiration
(FNA) or core biopsy versus surgical excision in the primary tumour (sic))
and differences in analysis of samples from different tissues are all
possible technical caveats that could cause a false discrepancy (pp. X351X352).
Hoefnagel et al. (2013), demonstrate that tumors among different metastases
within the same patient have 10% discordance with clinical consequences. This
result supports the heterogeneity of breast cancer and casts some concern about
relying on just one metastatic sample site for testing receptor status when
multiple sites exist. The data is clear that discordance exists, yet it is unclear as
to why. However, for this dissertation, the key question remains whether
discordances affect treatment decisions for patients and what are the
implications such decisions have on clinical outcomes.
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Impact on Treatment Decisions

First-line treatment plans in the metastatic setting are based on the receptor
status of the disease, along with other factors. Several authors, directly or
indirectly, explore the impact that retesting tumor receptors has on the
establishment of first-line treatment plans. These authors estimate the percent of
treatment plan decisions that occur based upon the receptor status of the
metastatic tumor, when that status is discordant with the primary tumor. Table 6
summarizes five articles that expressly address the impact of discordance on
first-line treatment plans.

Table 6. Change in Treatment Plans

Author
(Lindstrom et al., 2012)
(Aurilio et al., 2013)
(Dieci et al., 2012)
(Thompson et al., 2010)
(Amir, Clemons, et al., 2012)

Year
2012
2013
2012
2010
2012

Percent of First-line
Treatment Plans Changed
for MBC Patients Because
of Discordance
estimated > 50%
17 of 27 discordances
13 of 27 patients
24 of 34 patients
41 of 113 discordances

The Aurilio et al. (2013) article reports 17 of 27 discordances resulted in changes
to treatment therapies for MBC patients. Based on the reported data, it is not
possible to determine whether some changes are for the same patient, as the
data was reported by discordance, not by patient. While many changes to
treatment plans are also made for concordant receptors, the authors imply that
those changes are based on “… disease progression …” instead of the re-tested
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receptor results (Aurilio et al., 2013, p. 1651). Amir, Clemons, et al. (2012),
indicated 41 patients had their treatment plans changed after a metastatic biopsy
resulted in discordant results. One hundred thirteen changes in receptor statuses
were documented in the study. Because discordance is not clearly defined by the
authors, the 113 changes in receptor status can be interpreted in several ways.
That is, some of the changes may not indicate a change in standard therapy and
some changes may occur in the same patient (i.e. both ER and PR changed from
plus to minus). Thus, the 113 changes do not necessarily indicate 113 patients
had changes. The authors indicate that 14% of those patients whose tumors
were biopsied had their treatment changed based on the receptor status of the
metastatic tumor (Amir, Clemons, et al., 2012). It is important to note that this
14% is of patients whose tumors were biopsied, not the percent of those with

tumor receptor status discordance. It is unclear what percent of patients with
discordant results had their treatment plan changed.
Based on the body of research reviewed, I estimate that currently 60% to 75%
of MBC patients with discordance have their treatment plans changed based on
the receptor status of the metastatic tumor. Again, no statistical confidence can
be provided to this range due to the variation of, and uncertainty in the reporting
methods utilized by the authors included in this literature review. In chapter 4, I
report the percentage of discordant cases where the treatment plans are
changed in my retrospective study. Based on the current literature and
recommended clinical standards, doctors are performing more biopsies of
metastatic tumors, re-testing the receptor status and evaluating the discordance
with the primary tumor when determining first-line treatment plans. This
increased testing warrants the examination of clinical outcomes for patients with
first-line treatment plans based on metastatic tumor receptor statuses.
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Clinical outcomes

In the Conclusion sections of several articles, the authors summarize their
findings regarding the clinical outcome of discordant receptors (Chang et al.,
2011; Duchnowska et al., 2012; Idirisinghe et al., 2010; E. E. Lower, Glass, Blau,
& Harman, 2009; Montagna et al., 2012; Wilking et al., 2011). These particular
authors focus on the impact of discordance on life expectancy, without directly
testing the impact of changing treatment plans based on that discordance.
Additionally, some researchers note the clinical implications of changing
treatment plans in the Discussion sections of their papers, yet offer no definitive
statements in the Conclusion sections of their research. The lack of clearly stated
conclusions related to the clinical benefits of changing treatment plans make it
difficult to quantitatively summarize the literature. I utilized all the information in
the literature search, not just the authors’ stated conclusions, to ensure a
comprehensive analysis. The inclusion of all information led to clear, emergent
patterns that inform the clinical consequences of changed treatment plans.
The research derived from my literature review provides clear evidence that

changing treatment plans based on the metastatic tumor receptor status is more
harmful than helpful. A strong illustration of this finding is found in Liedtke et al.
(2009, p. 1953) where the authors assert that “discordant cases have poor
survival probably due to inappropriate use of targeted therapies.” The
implication is that patients with discordant receptor statuses are given
treatments contrary to what their primary tumor statuses indicate, and thus this
change is the likely cause of the poor results in life expectancy. The authors
report that the median post recurrence survival (PRS) rate for triple negative
breast cancer (TNBC) patients who have concordant receptors (thus no change
made to treatment based on metastatic tumor status) is 43 months. TNBC
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patients (primary tumor) whose metastatic tumor receptors were discordant,
experienced a 15.6 month median PRS (Liedtke et al., 2009, p. 1956). PRS
represents the survival rate of patients over time, calculated from the time the
metastatic recurrence is documented. This is the best and most common
measurement for clinical outcomes in the literature. Graph A in Figure 3 depicts
the TNBC patients only. Graph B represents the entire research sample.

Figure 3. Liedtke Discordance Results (p. 1956)

The authors imply that altering treatment plans for discordant patients translates
to poor clinical outcomes. Another example supporting the harmful outcomes
that result from changing treatment plans based on discordance is discussed by
Dieci et al. The authors indicate that “the impact of this approach on patient
management and outcome is not yet clear, (and) induce(s) clinicians to modify
the treatment choice in ~14% of the cases and that a change in the receptor
status is associated with poorer survival” (Dieci et al., 2012, p. 1). As noted
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earlier in this chapter, the 14% refers to the percentage of all biopsied patients,
not the percentage of patients with discordant receptors.
Niikura et al. (2012, p. 598), finds that “patients with HER2 discordance between
their primary and metastatic tumors have shorter OS. However, for our data,
inaccurate testing may have caused discordance between primary and metastatic
sites.” OS is the authors’ abbreviation for Overall Survival, which is equivalent to
Post Recurrence Survival (PRS). The authors’ reference to inaccurate testing
refers to measurement error. Figure 4 contains Niikura’s results.

Figure 4. Niikura Discordance Results (p. 597)

Karlsson et al. (2014, p. 1), notes that changes from ER+ or PR+ in the primary
tumor to ER- or PR- in the metastatic tumor result in an increased risk of death
with hazard ratios of 3.62 and 2.34, respectively. These patients had their
treatment plan changed and were denied endocrine therapy because of the
receptor status of the metastatic tumor. The authors note that none of the
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patients whose ER+ status changed to ER- received the endocrine therapy they
would have received had their receptors been concordant. This important result
supports my overall hypothesis and is shown in Figure 5. Note that in Figure 5
the worst performing patients are those whose ER status changed from positive
to negative.

Figure 5. Karlsson (p. 6)

In a study on HER2 discordance, Chang et al. (2011, p. 598), states that
changing treatment plans has “…an inferior outcome…” when compared to
concordant cases. While their sample size is small (n=18), the data analysis
supports my hypothesis. Those patients in Chang’s sample whose treatment plan
is based on the receptor status of the metastatic tumor in discordant cases had
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negatively impacted survival rates. Chang’s graphs are provided in Figure 6,
where Group 2 has concordant results and Group 3 has discordant results
(Chang et al., 2011, p. 597).
The weight of the literature review evidence indicates that changing treatment
plans based on discordant receptor status results yields poorer clinical
performance as measured by patient survival time post recurrence.

Figure 6. Chang (p. 597)

Potential Contradictory Data
Several articles provide some evidence that discordant results lead to equal or
better outcomes for patients. Amir, Miller, et al. (2012), find no difference in
survival rates for concordant and discordant results in MBC patients’ tumors.
They state “…after a median follow-up of 12 months, there were no trends for
an association between receptor discordance and either time to treatment failure
or overall survival” (p. 587). I have two concerns about their data. First, only
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about 30% of the discordant cases had their treatment changed based on the
receptor status of the metastatic tumor, as opposed to the 60% to 75% of cases
found in most of the literature review. Therefore, discordant and change in
treatment are not as confounded here as opposed to the typical studies in this
review, thus supporting the notion that no change in treatment plans leads to
better results. Additionally, the median patient follow-up is only 12 months,
which is not sufficiently long enough for estimating 5 year survival curves.
See Figure 7 for their results (p. 591).

Figure 7. Amir, Miller (p. 591)

E. E. Lower et al. (2009), researching only HER2 status finds that “… fifteen
percent of patients with primary tumors negative for HER-2/neu distant
metastasis had HER-2/neu overexpression. These patients experienced improved
survival compared to those patients with HER-2/neu negative primary and
metastatic lesions” (p. 305). In other words, 15% of the patients changed from
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HER2- in their primary tumor to HER2+ in their metastatic tumor. The authors
do not describe how patients’ metastatic treatment plans are determined.
Therefore it is not possible to determine the effect of first-line treatment
decisions in this study.
Duchnowska et al. (2012), find no difference in survival for discordant cases
when measured from the time of the initial diagnosis with breast cancer.
Evaluating survival from the time of initial diagnosis is not prudent in this
research. There are too many variables that affect overall survival times before
the recurrence, such as initial treatments, adjuvant therapies, age at diagnosis
and BRCA status. Survival time from recurrence is the best metric and the one
used in all other research I reviewed.
One article does conclude that better results are obtained by retesting receptors
and utilizing the metastatic tumor results. Their conclusion is “we observed that
18 out of 100 biopsied patients (18.0%) had a conversion of predictive factors
which allowed adjusting for therapy, … Those 18 patients showed a better
survival compared to the other 82 biopsied patients …” (Botteri et al., 2012, p.
284). The authors imply that 18 patients have discordant results and that those
patients’ treatment plans are changed based on the metastatic tumor status, and
those changes result in better clinical outcomes. My analysis of this article
exposed several research flaws. First, this study is restricted to patients with liver
metastases. Thus, it is not prudent to infer these results are applicable to other
locations of metastases. Second, the sample size of patients with changed
treatments is small, (n = 18). Third and most importantly, 10 of the 18 patients
with adjusted treatment plans do not necessarily have a change in HER2 status.
These 10 patients did not have their primary tumor tested for HER2 because
HER2 testing was not yet developed at the time of their initial cancer diagnosis.
These particular patients are HER2 positive in their metastatic tumor and they
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received Herceptin for the first time. The authors believe it is reasonable to
assume these patients were originally HER2- because about 80% of the current
patient population is HER2- in their primary tumor (p. 287). It is unreasonable to
make an assumption that impacts over half of the data (10 of 18). Additionally,
one could argue that since these patients had not initially been treated with
Herceptin and eventually had a recurrence, they are therefore more likely to
have been HER2+ in their primary tumor.
Summary of Clinical Implications
Foukakis et al. (2012), notes that, “…carrying out a metastatic biopsy had an
impact on treatment decisions … no conclusions could be drawn from these
analyses regarding the impact of this practice on survival” (p x351).
I disagree with Foukakis about drawing conclusions regarding the impact on
survival. The weight of the evidence is clear and indicates that basing first-line
treatment plans on the metastatic receptor status when discordant with the
primary tumor receptor status has an overall negative impact on survival.

Challenges Interpreting the Literature

I encountered two primary difficulties interpreting the findings and conclusions of
articles in the literature review. First, the definition of discordance often varies
from author to author and is sometimes not clearly defined. Additionally, it is
rare for an author to offer a definitive discussion about the impact of basing firstline treatment plans on metastatic receptors for patients with discordant
receptors. Together, these two challenges make it impossible to conduct a
precise quantitative meta-analysis of the literature review or easily make
comparisons between studies. The impact of the variation and ambiguity in
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discordance definitions has been discussed throughout this chapter. The difficulty
measuring the impact of changes in treatment plans based on inconsistent and
confusing reporting is best illustrated by Wilking et al. (2011). The key results
from this study are reflected in their graphical analysis presented in Figure 8. The
inserted note in Figure 8 is mine and not the authors.

Figure 8. Wilking Survival Curves (p. 558)

The authors indicate that there is indeed discordance in their dataset with
respect to HER2 and that changes in HER2 status resulted in a “significantly
increased risk of dying” for those patients (Wilking et al., 2011, pp. 557-558). My
interpretation of the authors’ description of the data is that each patient with
discordant metastatic receptors also had their first-line treatment plan based on
the metastatic receptor status instead of the primary receptors. Thus, change in

treatment plan is completely confounded statistically with discordance. A
statistical finding about discordance is also a statistical finding about changing
treatment plans based on the metastatic tumor receptors. This confounding is a
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problem throughout the literature and highlighted by Turner and Di Leo’s
literature review when they state that the “interpretation of the prognostic
impact of discordance is limited by the confounding influence of any treatment
alteration based on the metastatic biopsy result” (Turner & Di Leo, 2013, p.
950). The curves in Figure 8 indicate worse survival results for discordant
patients when compared to HER+ concordant patients. The key question is
whether that difference in survival can be attributed to the discordance or to
changes in patient treatment plans based on the discordance. That is, what
would the survival curves demonstrate if they are plotted based on whether the
patients’ first-line treatment plan is based on the primary or metastatic tumor
receptor statuses? In order to attempt to recast the analysis based on treatment
plan determination, I carefully reread the article to determine the first-line
treatment plans for the discordant patients; that is, are their treatments based
on the metastatic tumor or the primary tumor receptor status? This analysis
became a futile exercise. The authors’ data flow diagram is reproduced in Figure
9 (Wilking et al., 2011, p. 556). I inserted the lettering in Figure 9 for discussion
purposes. From the flowchart, it is clear that 43 patients (box E) have HER2+
primary tumors and 42 (boxes A and D) have HER2+ metastatic tumors. Fifteen
patients (boxes B and D) have discordant tumors. Utilizing the authors’ flowchart
and their commentary about that flowchart, I first concluded that 27 to 29 of the
43 patients with HER2+ primary tumors received trastuzumab (prescribed for
HER2+ cancer) after recurrence (p. 557). Based on this calculation, one would
assume that a maximum of 29 of the 42 patients with HER2+ metastatic tumors
received trastuzumab. The authors also indicate that all patients (42) with
HER2+ metastatic disease received trastuzumab (p. 557). The possible number
of patients treated for HER2+ metastatic cancer is now 27, 29 or 42. In another
section of this article, it is indicated that 23 to 26 patients are treated for HER2+
cancer (p. 557). After stating that all 15 discordant patients receive trastuzumab,
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Figure 9. Wilking Data Flowchart (p. 556)
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the paper indicates that “… of the 15 patients with change in HER2 status, 5
(33%) received trastuzumab” (Wilking et al., 2011, p. 557).
Based on the confusing information in the article, I cannot clearly determine the
number of discordant patients who had their treatment plans changed. A
reasonable interpretation is that most or all discordant patients have their
treatments changed based on the metastatic tumor status instead of the primary
tumor HER2 status. Figure 8 illustrates that discordant patients fared worse than
concordant ones. Thus, the obvious conclusion is that retesting the HER2
receptor status and basing first-line metastatic treatments on that test is harmful
to patients and should not be done. However, the authors state “the conclusion
of our study is that a number of patients, who experience a recurrence, will not
be managed correctly, if therapy is only based on characteristics of the primary
tumor” (p. 559). This type of confusion and confounding found in the data of the
relevant literature makes the study in this dissertation all the more necessary
and important.

Progress in the Literature

When I began the literature review, I expected to find that someone had
discovered the answer to my proposed research question: Does basing a

patient’s first-line treatment plan on the receptor status of metastatic tumors,
when discordant with the receptor status of the primary tumor, improve patient
outcomes? Most authors are researching the clinical impact of discordance, but
are not investigating how clinical outcomes are affected when the first-line
treatment plans of metastatic patients are based on the receptor status of the
metastatic tumor instead of the primary tumor. The most current research is still
35

focused on the survival impact of discordance, rather than the survival impact of
changing treatment plans based on the discordance.
One of the earliest articles I found on this subject was published in 1989 and the
stated purpose of the study in the article is to determine the prognostic impact of
ER discordance (Kamby, Rasmussen, & Kristensen, 1989, p. 1). Three years
later, Spataro et al. (1992), seeks to “… determine the clinical relevance of the
subsequent ER determination” (p. 733). Next, Kuukasjarvi, Kononen, Helin, Holli,
and Isola (1996) attempt to determine if a failure to respond to endocrine
therapy was due to discordance between primary and recurrent receptor status
(p. 2584). In 2005, the impact of changes in metastatic receptors on “… change
on survival” is investigated (Elyse E. Lower, Glass, Bradley, Blau, & Heffelfinger,
2005, p. 65).
Some 25 years after Kamby’s research, Yang et al. state:
The aim of this study was to evaluate the frequency and prognostic
impact of changes in the estrogen (ER), progesterone (PR) and human
epidermal growth factor receptor 2 (HER2) status between primary and
recurrent/metastatic lesions (RML) (Yang et al., 2014, p. 1).
After 25 years of research, Turner and Di Leo (2013) conclude that the data on
the clinical impact of discordance and changing treatment plans is “…limited,
inconclusive and conflicting” (p. 954). I disagree with this conclusion. Careful
reading of the available literature, which is not limited, indicates a conclusive
pattern that changing treatment plans based on the receptor status of the
metastatic tumor results in more harm than good, shortening the life expectancy
of metastatic breast cancer patients. The research in the literature that conflicts
with this pattern is limited and weak.
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Clinical Standards Recommendation

The current medical standards that relate to the topics of this dissertation are
discussed earlier in this chapter. Based on my review of the literature, I offer the
following over-arching standard of care for metastatic breast cancer patients with
discordant receptor status results:

Where discordance between the primary and metastatic tumor receptor status
would indicate different treatments, the status of the primary tumor should take
precedent when developing the first-line treatment plan for a newly diagnosed
recurrent metastatic breast cancer patient. Strong clinical evidence to the
contrary must be present to warrant basing the treatment plan on the metastatic
tumor receptor status.
This statement, combined with the non-contradictory standards of ABC2 and
NCCN, coupled with the excellent decision flowcharts of Turner and Di Leo
(2013) and Penault-Llorca et al. (2013) provide clear direction for the best
course of action based upon current available literature and supporting data. My
proposed standard is challenged for efficacy in the data analysis phase of my
research.

Statistical Literature Review

In preparation for the analysis phase of this dissertation, I performed a brief
literature review on the Kaplan-Meier (KM) method of survival analysis and the
log rank method of testing KM survival curves (Lakatos, 1988). Most papers on
this subject are either theoretical (the mathematical theory, or new theories
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about calculating sample size) or theoretical with some practical examples. The
methods referencing sample size estimation ultimately rely on some form of a
normal approximation of the sum of hypergeometric probabilities based on the
number expected deaths. The number of deaths is manipulated by the censor
and death percentages to obtain an estimate of sample size and power
calculations (Lakatos, 1988, pp. 223-224). Several practical points are found in
the articles reviewed. With respect to the number of time intervals utilized in an
analysis, “there are no big differences in power if the subjects are observed in 2,
4, or 8 time intervals” (Jozwiak & Moerbeek, 2011, p. 637). Additionally on time
intervals, “ …increasing the sample size generally has a greater effect on power
than increasing the number of time points. …it is better to recruit a large number
of participants in the trial and observe them infrequently, for example, two or
three times during the study” (Jozwiak & Moerbeek, 2011, p. 651). The impact
that the hazard rate has on power depends on how close the rate is to zero or
one, not just the difference between the two proportions (p. 650).
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CHAPTER 3
Materials and Methods

Research Purpose

The goal of my research is to influence change in international and national
medical standards that determine the first-line treatment plans in discordant
cases of metastatic breast cancer, and provide a higher level of evidence for
those standards. The purpose of this dissertation was to determine the impact on

patient outcomes in recurrent metastatic breast cancer diagnoses with discordant
receptors when the first-line treatment plan is based on the receptor status of
metastatic tumor(s) instead of the receptor status of the primary tumor(s).
For my particular study, the first-line treatment plan was defined as the first
treatment strategy administered after the diagnosis of a metastatic recurrence,
when the receptor status of the metastatic tumor is discordant with the primary
tumor, or the first treatment plan after establishing discordance if the testing of
the metastatic receptors is performed routinely and not ordered because the first
treatment plan is failing. (In the metastatic setting, treatment plans will
inevitably change over time as the efficacy of one strategy fails and another is
employed).
For the purpose of this study, patient outcomes was defined in two ways: 1) five
year post recurrence survival time (PRS) curves, which will be calculated as the
time from metastatic recurrence to the time of death or censoring, and 2) the
first-line follow-up scan results using the RECIST (Eisenhauer et al., 2009)
standard, defined in Appendix 4. The first follow-up scan typically occurs 90 days
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after the first-line treatment is initiated. Scan refers to some form of imaging to
assess the growth of the metastatic tumors.
It is important to note that in the absence of re-testing the metastatic tumor
receptor status, first-line treatment plans are based on the receptor status of the
primary tumor, previous treatments and the clinical observation of the patient.
When the metastatic tumor is retested, sometimes the receptor status of the
metastatic tumor is utilized instead of the status of the primary tumor when
determining treatment plans. In this study, the first-line treatment plan was
considered to be based upon the test results of the metastatic tumor(s) if: a)
there was a discordance between the primary tumor receptor status and the
metastatic tumor status, and b) that discordance indicated a different treatment
plan, and c) the plan was based on that discordance. All three of these
conditions must have existed to consider the first-line treatment plan to have
been based on the metastatic tumor instead of the primary tumor.

Key Research Questions

Two research questions are postulated for my study:
1. Does basing a patient’s first-line treatment plan on the receptor status of
metastatic tumors, when discordant with the receptor status of the
primary tumor, improve patient outcomes?
2. Should the first-line treatment plan in metastatic cases be based on the
receptor status of the primary tumor or the metastatic tumor?
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These two questions guided the research methodology of this study and are
critical questions not addressed in the literature.

Hypothesis

In discordant case, if the first-line treatment plan is based on the receptor status
of the primary tumor, the median life expectancy of MBC patients will be longer
than MBC patients whose first-line treatment plan is based on the receptor status
of the metastatic tumor.

Study Design

A retrospective observational study was designed utilizing the data of the
patients diagnosed with recurrent metastatic breast cancer in The University of
Tennessee Cancer Center’s tumor registry. A retrospective study was the
appropriate design since a prospective study could take 10-15 years to complete
and ensuring sample randomness would be difficult. That is, the medical staff’s
awareness that a study was being conducted and exposure to the hypothesis
could theoretically impact the decision making process and bias the data. A
clinical trial would be possible, but again would likely take more than 10 years to
complete. Additionally, ethical concerns have been proposed by other authors.
Amir, Clemons et al. (2012) state “a more definitive assessment of biopsy would
require a randomized trial… …for such a trial would likely it (be) unfeasible” (p.
713). Aurilio et al. (2013) state “in our opinion, only high powered prospective
and randomized trials could clarify the outcomes in this field and finally
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demonstrate a survival benefit; however, they should involve large sample size
and ethical controversies may be unsolvable” (p. 1655). I disagree with the
statement that only prospective randomized trials could clarify the outcomes. I
contend that my retrospective study, and other similarly executed retrospective
studies, can provide the necessary data to address the hypothesis and research
questions posed in this paper.

Discordance

Discordance was a critical concept introduced and discussed in Chapter 2. The
most common definition of discordance in the literature is defined as a difference
in the receptor status of the primary and metastatic tumor tests. Of the eight
combinations of receptor status listed in Table 5, Chapter 2, there are only four
combinations (called phenotypes) that traditionally dictate treatment decisions.
Those four phenotypes are displayed in Table 7.
Phenotypes and Discordance
This study focused on patients whose metastatic tumors were reassessed and
determined discordant. Discordance was strictly defined as a difference in the
primary tumor receptor status and the metastatic tumor status that warrants a
change in treatment plan based on current NCCN standards (NCCN.org, 2014,
pp. BINV-4). The four phenotypes utilized for this study are TNBC (Triple
Negative Breast Cancer), HR+ (Hormone Receptor positive and HER2 negative),
HER2+ (HER2/neu positive and HR negative), and PBC (Positive Breast Cancer).
Radiation treatment was not considered in my study because it is agnostic to
receptor status. Table 8 delineates the basic treatment strategy descriptions by
phenotype. Dieci et al. (2012), also uses these four phenotypes in their research.
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Table 7. Receptor Phenotypes

Receptor
Combination

Description

Phenotype

ER-, PR-, HER2-

Triple negative

TNBC

ER+, PR+, HER2-

Hormone Receptor (HR) positive

HR+

ER+, PR-, HER2-

ER positive, PR negative

HR+

ER-, PR+, HER2-

ER negative, PR positive

HR+

ER-, PR-, HER2+

HER2 positive, HR negative

ER+, PR+, HER2+

Positive Breast Cancer

PBC

ER-, PR+, HER2+

HR positive, HER2 positive

PBC

ER+, PR-, HER2+

HR positive, HER2 positive

PBC

HER2+

Table 8. Phenotype Treatments

ER

PR

HER2 Phenotype Primary Treatment

1

-

-

-

TNBC

Chemo

2

+

+

+

PBC

Chemo+Targeted, Endocrine

3

+

-

+

PBC

Chemo+Targeted, Endocrine

4

-

+

+

PBC

Chemo+Targeted, Endocrine

5

+

+

-

HR+

Chemo, Endocrine

6

+

-

-

HR+

Chemo, Endocrine

7

-

+

-

HR+

Chemo, Endocrine

8

-

-

+

HER2+

Targeted
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Liedtke et al. (2009), report an analysis of TNBC and RPBC, which the authors
define as any positive receptor and de Duenas et al. (2014), utilizes three
phenotypes (HR+, HER2+, TNBC). In this dissertation, discordance was strictly
defined as a change from one of the four phenotypes to one of the remaining
three; thus there were 12 (4x3) possible discordances.

Study Decision Flow

Figure 10 is a graphic depiction of the study protocol flow and cohorts. This
study began with isolating patients in the Tumor Registry who had a recurrence
of metastatic breast cancer. The next step was to determine whether or not the
MBC patient had their receptor status re-tested (cohorts A and B in Figure 10),

Figure 10. Study Decision Flow
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and if available, the rationale for such re-testing. For retested patients, a
determination was made to whether their primary and metastatic tumor receptor
statuses were concordant or not (C and D). For patients who tested discordant, it
was then determined whether their first-line medical treatment plan was based
on the primary or the metastatic tumor receptor status. These two groups are
represented as cohorts E and F in Figure 10.
The main objective of this study was to compare groups E and F (treatment plan
based on primary versus metastatic tumor). My literature review revealed
studies that compared groups A and B, and C and D as depicted in Figure 10,
however no research explicitly carried out a protocol to compare survival rates of
groups E and F. For example, one article on liver metastases compared the
survival impact on patients with re-tested tumors to those patients whose tumors
are not re-tested (A and B). The researchers found no difference in overall
survival rate between these two groups (Botteri et al., 2012). My research
project also evaluated groups A and B to determine any difference in survival
rates, and to determine whether that difference indicated a potential bias in the
data. My concern was that it might be possible that patients were re-tested
because the doctor’s clinical intuition indicated that a more aggressive treatment
was needed. This type of bias was important to understand in a retrospective
study because if patients in branch B were not representative of the population
of all metastatic patients, then this bias could impact the interpretation of
comparisons of groups C to D and E to F.
The articles in the Literature Review section that evaluate the clinical impact of
discordance did so by comparing patients with concordant versus discordant
tumors (groups C and D). In studies that evaluate the survival rates of patients
in cohort C versus cohort D, cohort D patients are always, to some degree,
confounded with cohort F. My analysis is unique since this confounding effect is
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removed by specifically comparing the survival curves of groups E and F.

Data Parameters

Based on my protocol, I identified the list of variables necessary to conduct my
research. The information needed for my variables was found in The University
of Tennessee Cancer Center Tumor Registry, the electronic medical record and
paper charts of the patients in the study.
Variables in the Tumor Registry
The data collection began with a request to the Tumor Registry manager to
export variable information based upon my protocol criteria for patients with
recurrent metastatic disease (local recurrence in the breast was not considered).
I requested records on patients with recurrences after January 1st, 2000 and
before November 1, 2014. This time period was chosen for my study because
HER2 testing was not available until 2000. However, I suspected I would
encounter missing data in the early records since HER2 testing was also not
routinely performed until around 2005 (Harries & Smith, 2002). In order to
ensure accuracy, I eventually asked the manager for access to all patient data in
the tumor registry. I then personally managed the data to extract the variable
information I sought. The manager informed me that some new information
fields were added to the tumor registry database in 2010. Therefore, this
additional information was missing in records dated prior to 2010, thus rendering
the data problematic to utilize if it could not be found in other sources. Further
discussion and definitions of the variables actually used in the analysis are
provided in the Results section of this dissertation.
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Variables in Electronic and Paper Charts
Some of the key variables necessary for my research were not routinely stored in
the Tumor Registry. These particular variables were obtained from a review of
patient charts (both electronic and paper). Additionally, I was able to verify and
often complete missing variables in the Tumor Registry data through these chart
records. I performed all the tumor registry, electronic records and paper chart
reviews with assistance and quality control from the Tumor Registry manager.
Further discussion and definitions of the variables actually used in the analysis
are provided in the Results section of this dissertation.

Quality Control

Operational definitions of key variables were established and are found in
Appendix 4. These definitions were vetted by the Tumor Registry manager, and
aligned with industry standards. The registry manager and I reviewed the first
ten patient records together to establish a common practice.
Record Keeping
Both paper and electronic records were created during the data collection
process. I created a paper data collection form that listed the key variables
sought from each patient record review. A copy of the form is found in Appendix
5. The form did not contain a direct patient identifier; only a code number,
connecting the sheet to the patient, was employed. The code numbers and
patient identifiers were maintained separately from the data collection sheets.
Data collection forms will be destroyed once the electronic data set is complete,
the quality control has been performed, and this dissertation is complete. Each
electronic patient record’s code number was assigned by random number to
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ensure confidentiality. Separate Excel spreadsheets were created that contain
the decoding information in one file and the raw data without identifiers in
another file. The decoding file was password protected and kept separate from
the raw data. JMP files for analysis will not contain patient identifiers.

Confidentiality and Compliance

Confidentiality is important in any medical research. I followed and completed
the requisite procedures for IRB approval as required by both the University of
Tennessee Medical Center and the University of Tennessee, Knoxville. Both IRB
protocols required for my research were approved by expedited review.

Statistical Considerations

A priori statistical methods, hypotheses and sample size considerations are
outlined in this section.
Sample Size and Power
It is important to determine the sample size in any research endeavor to ensure
the objectives of the experiment are achieved and the hypothesis can be proven
or not. In order to estimate sample size needs with respect to statistical power
for survival analyses, several statistics needed to be known or estimated (power
and other terms used in this section are defined in Appendix 12). Estimate of the
survival curve characteristics under the null hypothesis, a hazard ratio (HR) for
the alternative hypothesis, and the risk of a false positive were required to
estimate the needed sample size. For my sample size considerations, I assumed
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that a potential difference in median life expectancy greater than one year
existed between those metastatic patients with discordant receptors whose firstline treatment plan was based on their primary tumor receptor status as opposed
to the metastatic tumor receptor status. The hypothesized one year median
difference was supported by the evidence in my Literature Review section
(Chang et al., 2011; Liedtke et al., 2009; Niikura et al., 2012). This median
difference translated to an approximate hazard ratio of 1.4. Therefore, at any
point in time, a metastatic breast cancer patient was 40% more likely to die if
their treatment plan was based on their metastatic tumor receptor status instead
of their primary tumor results.
Major databases such as SEER do not currently collect data on recurrent
metastatic breast cancer survival statistics. A few estimates of overall survival
curves are found in the literature; however, I elected to combine and average
data from five articles in the literature review to estimate the survival curve for
recurrent metastatic breast cancer. The exact raw data required to calculate the
survival curve was not always delineated in these papers. In some cases, I
extrapolated data from graphical representations. It was important to recognize
that this combined data produced a biased sample for the overall population
because the samples in each study only contained cases where receptors were
re-tested. However, this was a logical solution to establish survival curves for my
research since I was only concerned with cases where tumors were re-tested.
Table 9 summarizes the data extracted from the four articles and the (CTCA,
2014) website that was then utilized to establish an average survival curve. The
CTCA data was the only available survival curve I located in my search that
directly focused on metastatic breast cancer. The resultant average survival
curve, depicted in Figure 11, had a median survival of 1.85 years and produced a
five year survival rate (x-axis) of approximately 20% of the data population (yaxis).
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Table 9. Literature Survival Data

CTCA
1
0.78
0.66
0.57
0.5
0.42
0.37
0.32
0.29
0.25
0.23

Tev
1
0.8
0.68
0.57
0.5
0.39
0.31
0.28
0.2
0.19
0.18

Daw 08
1
0.78
0.65
0.54
0.47
0.42
0.38
0.32
0.295
0.25
0.2

Chia
1
0.79
0.62
0.5
0.39
0.32
0.295
0.22
0.2
0.18
0.17

Figure 11. Null Survival Curve
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Daw 10
1
0.81
0.72
0.62
0.52
0.47
0.39
0.32
0.28
0.26
0.22

Year
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5

Average
100.0%
79.2%
66.6%
56.0%
47.6%
40.4%
34.9%
29.2%
25.3%
22.6%
20.0%

The overall average survival curve postulated in Figure 11 was a combination of
patients with concordant and discordant receptor statuses and different
treatment plans based on either the primary or metastatic tumor receptor status.
Because the overall average survival curve depicted patients with different
receptor statuses and treatment plans, I then extrapolated two survival curves
from the overall average survival curve. These curves represented the null and
alternative hypotheses consistent with my estimate of one year median survival
difference between patients whose treatment plans were based upon their
primary or metastatic tumor receptor status, represented by cohorts E and F in
Figure 10. Figure 12 illustrates the two hypothesized curves for groups E and F. I

Figure 12. Null and Alternative Curves
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chose .01 as the risk of a false positive in my analysis. With an estimated survival
curve, a hypothesized HR and the risk of a false positive, the statistical power
could be calculated for any given sample size; conversely, for a given power the
required sample size could be calculated.
Both SAS and JMP software were utilized to determine sample size needs for my
research. SAS software’s two sample survival piecewise application allowed for
calculating the optimal sample size estimate for my study. This methodology
required the input of the average survival rates in half-year increments, utilizing
data from Table 9. The resulting SAS power curve estimates yielded an optimal
sample size of approximately 50 patients per cohort (E and F) of the study.
These curves are shown in Figure 13, Utilizing JMP, a sample size was estimated

Figure 13. SAS Power Curves
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using a two sample proportion test based on the percentage of patients surviving
after five years under the null and alternative hypothesis and a chosen type I risk
of .01 and power of .90. This calculation also yielded an optimal sample size of
50 for each cohort in the study (groups E and F), as shown in Figure 14.

Figure 14. JMP Power Calculation

Sample Size Discussion
The above statistical exercise was important to determine the optimal sample
size for this study. The fact that both calculations resulted in a consistent
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answer of 50 patients per cohort was validating. At the time I wrote the
research proposal to examine MBC patients, receptor statuses, and treatment
plan decisions, the tumor registry manager estimated that my total sample size
for the project would be between 100 and 200, yielding only 10 to 20 patients in
each cohort of the study (E and F). These numbers were disappointing, but not
a surprise. The available sample size for sub sample categories A-F in Figure 10
were certainly bound by the existing data in the Tumor Registry and the
accessible paper and electronic charts at the time of data collection for this
dissertation. The actual sample sizes are reported in Chapter 4.
A Priori Analysis Plans
During the proposal stage of this dissertation, my a priori analysis plans were as
follows: The first analysis will be a Chi-square test, analyzing the null hypothesis

asking whether the two patient groups, E and F, have the same percentages of
patients in five categories, 4 RECIST categories plus the deceased category I add
to the study, (as defined in Chapter 1). Statistically significant results may lead to
further refined tests. The five categories will then be combined into two
categories: Complete Response (CR), Partial Response (PR) and Stable Disease
(SD) will be combined into one category; Progressive Disease (PD) and Deceased
(D) will be combined into a second category and analyzed with a Chi Square test.
Next, utilizing the groups identified in the study decision flow, Kaplan-Meier
survival curves will be calculated for all paired comparisons (A and B, C and D, E
and F). The sample will also be examined using Cox Proportional regression in an
effort to account for the effect of covariates, since this is not a randomized trial.
All available covariates will be tested. The literature review indicates possible
significant covariates will be age, time to recurrence, HR status, initial stage and
initial lymph node involvement.
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Log Rank, Wald and other generally accepted tests for survival analysis will be
executed. Univariate tests will be performed and reported on available
covariates. Descriptive statistics will be reported on each group of patients
(cohorts E and F). JMP Pro version 10.0 will be used for all analyses. Other
software may be used for graphics and data management.
Statistical Significance
Surprisingly, a p-value (or critical value) of .05 was the most frequently utilized
value of statistical significance in the literature. Given the randomization
limitations of observational studies and the risk that non-significant results do not
get published, a critical value of .01 would be a more prudent statistical measure
in medical research. In other words, if 20 experiments are performed with a type
1 risk of .05, then one experiment is likely to be deemed statistically significant
by chance. If the other 19 experiments are not published, a literature review
would find one paper supporting a hypothesis and not reveal the 19 that do not
support the hypothesis. One article recently reported a study showing that only
17% of clinical trials had been published one year after completion ("Spilling the
Beans," 2015). The use of p-values has also come under scrutiny. Gigerenzer
and Marewski (2014), offer several criticisms of p-values, including the
cumulative risk of performing numerous tests and that spurious correlation can
lead to statistically significant results, yet non-reproducible results . Based on the
works just cited and holding myself to high standards, I elected a priori to pair
evaluative statements with the varying degrees of possible statistical significance
values my data might yield.
The following are my evaluative statements I developed based on possible pvalues for key analyses of my research. Test results numerically consistent with
my hypothesis that patients live longer when their first-line treatment plans are
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based on the primary tumor receptor status instead of the metastatic tumor
receptor status in discordant cases will be described as:
•

consistent with the hypothesis for p-values greater than .05;

•

supporting (providing corroborating evidence) the hypotheses for p-values
between .01 and .05; and

•

demonstrating (shown to be true by reasoning or adducing evidence) the
hypotheses for p-values less than .01.

For sample data numerically inconsistent with my hypothesis showing that
patients die sooner when their first-line treatment plans are based on the
primary tumor receptor status instead of the metastatic tumor, my results will be
described as:
•

not consistent with the hypothesis for p-values greater than .05;

•

not supporting the hypothesis for p-values between .01 and .05; and

•

refuting (thus proving to be false or erroneous based on the data) the
hypothesis for p-values less than .01.

Statistical Methods Review

The Kaplan-Meier (KM) method of survival analysis has been a standard in
medical industry research literature (Richard Van Noorden & Brendan Maher,
2014). All articles that compare survival curves in my literature review utilize this
method. In my review of the literature, statistical conclusions were being
reached using small sample sizes; thus I decided to research the key features
impacting the statistical power of the Kaplan-Meier method and perform Monte56

Carlo simulations to add to my practical knowledge of the KM technique. The
research was performed and the simulations designed to answer several
important questions:
•

What is the power of KM tests with sample sizes smaller than 20?

•

How is power affected by binning the data versus having continuous
measurements?

•

Does the number of bins (time intervals) affect power?

•

How is power affected by censoring?

•

How is power affected by unequal sample sizes when comparing two
survival curves?

Simulation
While the statistical literature review provided some insight into the attributes of
statistical power associated with the KM method of survival analysis, none of the
articles reviewed provided a clear clarification of my questions about power. I
therefore elected to utilize simulation to address my questions on the statistical
power of the KM method. Key definitions for terminology used in the simulation
are in Appendix 12. For simulation purposes, I translated the average survival
curve previously discussed in this chapter to a statistical model utilizing an
exponential distribution [(1/λ) e1/λ] parameterized with lambda = 3.5. This
function provided a reasonable estimate of the hypothesized survival curve. In
order to explore the power of the KM method using the log rank statistic, the
following six attributes were manipulated: sample size (n1=n2= 10, 20, 30, 50,
100, 200, 500, 1000), sample size distribution (p1 = p2 = 50%; p1 = 70%, p2 =
30%; p1=85%, p2=15%), hazard ratio (delta = 1.0, 1.25, 1.5, 1.75, 2.0, 3.0),
survival function (exponential, lambda = 2, 3.5, 5), binning (continuous
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recording, 10 bins, 5 bins, 2 bins) and censoring (none, 25%, 50%).
MATLAB R2015a was used to conduct the simulation. All programs were used
with permission. Figure 15 provides a flowchart of the simulation process. For
the power calculations, the simulation was executed 10,000 times, giving the
maximum width 95% confidence interval for the estimates using the normal
approximation to the binomial as +/- .0049 or .49%. Appendix 13 contains the
MATLAB file names and descriptions used in the simulations. The code for each
program is found in Appendices 14-21.
Simulation Results
The simulation results clearly indicated that sample sizes less than 20 per group
yielded insufficient statistical power. The simulation results in Table 10 (alpha =
.01) and Table 11 (alpha = .05) detail the power estimates with the following
conditions: no censoring; lambda = 3.5; equal sample sizes; and continuous
recording of data. These tables show a hypothesized hazard ratio of two or more
would be necessary to reach any reasonable level of power. From a practical
standpoint in breast cancer research, an HR of 1.25 would be medically
important. For instance, in the much cited Journal of American Medical
Association (JAMA) article on hormone replacement therapy and breast cancer,
the sample HR supporting hormone replacement therapy is a cause of breast
cancer is 1.26 (Rossouw et al., 2002). In Table 11, for n1=n2= 10 and HR =
1.25, the assumed probability of a false positive (alpha = .05) and the chance of
a true positive (power) are both 5%. Thus ½ of the positive results under these
conditions would be false. To ensure the kind of power needed to produce a
successful research outcome with HR = 1.25, sample sizes of greater than 500
sizes were needed. This demonstrated why important clinical trials involve large
sample sizes, illustrated by the hormone replacement study that involved over
8,000 women in each cohort of the study (Rossouw et al., 2002). Observational
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Figure 15. Simulation Flow
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Table 10. Power Table for L3.5 C0 C .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0067 0.0116

0.0249

0.0467 0.0736

0.234

0.006

0.0179

0.0542

0.122

0.0088 0.0448

0.1994

0.4516 0.6989 0.9933

0.007

0.1021

0.4804

0.8282 0.9702

1

0.0086 0.2582

0.854

0.9929

1

1

0.0069 0.7015

0.9997

1

1

1

0.0117 0.9693

1

1

1

1

2

3

0.2256 0.6535

Table 11. Power Table for L3.5 C0 C .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

0.0342 0.047

1.5

1.75

0.0882

0.1408 0.2016 0.4819

0.0349 0.0744 0.1599

0.2992 0.4566 0.8585

0.0437 0.1439 0.4075

0.6893 0.8752 0.9994

0.0394 0.2584 0.7111

0.9447 0.9946 1

0.0434 0.4881 0.952

0.9989 1

1

0.0436 0.8761 0.9999

1

1

1

0.0511 0.9931 1

1

1

1
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studies tend to have smaller sample sizes and are generally based on the data
available to the researcher, as Table 20 in Chapter 4 illustrates.
The simulation results indicated there were no practical differences in power
when continuously recording each data point or binning the data. Tables 11 and
12 illustrate this result and show that any differences in the simulated power
were either within the margin of error or of no real practical significance. As a
scientist, I intuitively wanted to know the exact time of failure (death) for each
data point, believing that information would have provided a more detailed
analysis than just knowing the failure occurred within a certain time interval.
However, since the ultimate measure was binary, it was important to realize that
similar statistical results applied to both the percent of events that occurred over
time versus at the end of a time period. Knowing exact time of death was

Table 12. Power Table for L3.5 C0 B10 .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.0315 0.0429

0.0808

0.131

0.0334 0.0697

0.1498

0.2899 0.4401 0.8472

0.0433 0.1415

0.4035

0.6843 0.8708 0.9994

0.0383 0.2559

0.7075

0.943

0.9938

1

0.0435 0.4829

0.9503

0.9988

1

1

0.0431 0.8735

0.9999

1

1

1

0.0515 0.9931

1

1

1

1
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2

3

0.1918 0.4611

therefore inconsequential to the power. A priori, I assumed that the loss of
information resulting from utilizing less instead of more bins would have a
tremendous impact on power. The literature and my simulation indicated that
the number of bins was not that important to power.
The literature states larger samples observed less frequently (binned) are better
than smaller samples observed more frequently. My simulation results supported
the statistical literature review outlined in Chapter 2. While there were some
differences in power based on the number of bins, those differences were
negligible when compared to the impact sample size had on power. To illustrate
this point, in Table 12 the power for n1 = n2 = 20 and a HR of 3 is 85% for ten
bins and for the same set of variables with only two bins is 69% (Table 13).
These differences warranted scrutiny, but were not as large as I expected. Once

Table 13. Power Table for L3.5 C0 B2 .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.018

0.028

0.0489

0.083

0.1141

0.2697

0.0253

0.0513

0.1182

0.2218

0.3333

0.689

0.035

0.1145

0.3502

0.6027

0.8041

0.9947

0.0367

0.2317

0.6534

0.9081

0.9842

1

0.0401

0.4556

0.9289

0.9977

1

1

0.0436

0.8499

0.9999

1

1

1

0.0469

0.9909

1

1

1

1
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the sample size reached 50, the power differences between 10 and two bins was
minimized. The primary concern with binning, (especially with less than 5 bins),
is that the statistical significance between two populations can still be tested, but
the visual evaluation of proportional hazards is hindered as the number of bins is
reduced. The extreme case of utilizing only one bin in which results were
observed once at the end of a time period provides excellent statistical
knowledge when comparing two groups at that point in time, but would garner
no information about the comparative shapes of the survival curves over time.
I had no experience with analyzing data that might be censored, so when I
investigated survival techniques, censoring was a concern, especially its affect
upon power. Descriptions of the KM method and the log rank test indicate that
these methods were created for censored data, so I utilized the simulations to
better understand the impact censoring had on data analysis results. Tables 11
and 14 best illustrated the effect of censoring. Table 14 was the result of 50%
censoring; thus these numbers could be compared to Table 11 that had no
censoring. Stated differently, sample sizes of 50 with no censoring could be
compared to sample sizes of 100 with 50% censoring. These two results were
nearly identical with respect to power. This outcome was consistent with the
literature which indicates the real issue at stake is the number of events (deaths)
not the pure sample size.
Common statistical calculations and concepts indicate that sample sizes of equal
value are optimal when comparing two groups (Snedecor & Cochran, 1967, p.
104). In other words, if the total sample size is 20 for two groups, then it is
statistically more effective to have an equal division between those two groups
(i.e. 10 in each group), than any other combination. If the two groups’ samples
were split 16 and 4 respectively, the lack of data in the second group (n2=4)
would negatively impact the ability to compare that group with the other, even
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Table 14. Power Table for L3.5 C50 C .05
Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0277 0.0361

0.0512

0.0738 0.0966 0.2133

0.029

0.0482

0.0872

0.1497 0.2081 0.4711

0.0348 0.0856

0.209

0.3738

0.0396 0.1429

0.4006

0.6915 0.8648 0.9981

0.0448

0.269

0.7135

0.9439 0.9926

0.0444 0.5867

0.9801

1

1

1

0.0438 0.8722

0.9999

1

1

1
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0.539

0.9059

1

though the other group had more data (n1=16). The simulation results strongly
supported the concept of equally distributed sample sizes for comparative
purposes. Tables 11 and 15 best illustrate this concept, where n1 is the sample
size of the null distribution. Comparing n1 + n2 = 100, where one sample is split
evenly (n1+n2=50) and the other sample is split disproportionally (n1=85 and
n2= 15), dramatic differences in power occurred. Power was reduced over 50%
when employing unequal sample sizes in the simulation even though the total
sample sizes were the same.

Table 15. Power Table for L3.5 C0 C N85/15 .05

Hazard Ratio
n1,n2
3, 17
6, 34
15, 85
30, 170
60, 340
150, 850
300, 1700

1

1.25

1.5

1.75

2

3

0.035

0.031

0.0358

0.0486

0.0641

0.1487

0.0377 0.0387

0.0628

0.1097

0.1666

0.4378

0.0374 0.0622

0.1773

0.33

0.5009

0.9019

0.0439 0.1194

0.3555

0.6332

0.825

0.9972

0.0392

0.231

0.6571

0.9212

0.9858

1

0.0423 0.5445

0.9714

0.9998

1

1

0.0479

0.9999

1

1

1

0.843

Type 1 Error
An interesting pattern appeared in all the data and is illustrated in Table 14. A
hazard ratio of one meant that the two groups did not differ in hazard rate.
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Thus, the type 1 error rate in the simulation was estimated where HR = 1. For
all simulation runs, the actual type 1 error rate was lower than the declared rate
for sample sizes under 1,000. The simulation’s actual rate came close to the
declared rate as n1 + n2 approaches 2,000. For example, in Table 14, with n1 =
n2 = 10, the simulated alpha is .028 versus the declared rate of .05. That is,
there were only 2.8% of the 10,000 p-values in the simulation exercise less than
.05 where the HR = 1. For n1 = n2 = 1,000, the simulated rate is .044,
approaching the declared rate of .05. These results, as simulated, would indicate
the log rank test is conservative with respect to the type 1 error.
In summary, when comparing the data of two groups of subjects utilizing the KM
and log rank methods, the key issue is the number of events (deaths) that will
occur over the time of study. For estimating the sample size needed ahead of the
research project’s implementation, to calculate power or desired sample size, an
estimate of the rate of events (deaths) occurring and the potential censoring rate
are needed. Of less importance is the number of observation intervals, so that
given the choice, it is better to have more subjects observed less often, than to
have fewer subjects observed more often. However, for a clear picture of
survival curve shapes, five to 10 bins are recommended. The most important
factor to consider and attempt to control is obtaining even splits of the total
sample size. This split is easier to control in a prospective study. In a
retrospective study, the researcher may not be able to control the split of data at
all, as the sample is based on the data available. All power tables for the various
simulation combinations are shown in Appendix 11.
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CHAPTER 4
RESULTS AND DISCUSSION

Data Acquisition

After receiving IRB approval, The University of Tennessee Cancer Institute
provided access to the tumor registry data, electronic records and where
possible, paper patient charts. The tumor registry was queried for recurrent
metastatic breast cancer patients. Several initial queries were performed by the
Tumor Registry manager that yielded varying sample size results each time.
Based on these queries, I requested a wider query that allowed me to pare down
the data manually where needed, yet was more likely contain all possible records
for review. Appendix 6 contains a flowchart view of the data collection process.
Data Cleaning
All data analysis processes must begin with the cleaning of the data. Table 16
shows a listing of file names that represent the progression of the cleaning of the
data. Each step in the data cleaning process is described below.

Table 16. Key Data File Names

Step

Excel File Name

Number
of Rows

1

1 Copy of Breast Recurrs from 1990 As Received

3183

2

1.1 Copy of Breast Recurrs from 1990 SORTED

3182

3

1.3 Copy of Breast Recurrs from 1990 SORTED

605

4

1.4 Copy of Breast Recurrs from 1990 SORTED

587

5

1.521 Breast Recurs START

586
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Step 1. A copy of the file received from the Cancer Center was made. This file
had 79 columns (variables) of data.

Step 2. Two columns were added to the original file and one blank row deleted.
A column to number (order) the rows as a safety precaution was added, in case
the data was ever erroneously sorted in a way that could cause a loss of
structure. An additional column entitled Group was inserted to combine records
that appeared to cover several rows.

Step 3. Rows that were blank or duplicated based on the query output were
removed. Records in which a diagnosis was initially Stage 4, thus not recurrent,
were removed. A few records were deleted that had no recurrence data,
incomplete data and contained phrases like “disease free” and “never” in the
recurrence description. All records with the recurrence date prior to the year
2000 were deleted. Another column was created to store additional recurrence
date(s) for patients with more than one recurrence. Patient records that
appeared in more than one row were combined into one row.

Step 4. Additional duplicate patient records were discovered and removed. The
586 remaining records consisted of the following combination of records:
a. Recurrence dates
i. 114 with 11/11/11 as the recurrence date (this was deemed
a filler date for incomplete records)
ii. 212 with missing recur date
iii. 260 with a recur date
b. Recurrence location
i. 151 distant
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ii. 41 distant with a long description
iii. 115 unknown
iv. 40 regional
v. 30 local (not intended to be included in this study)
vi. 210 never disease free (possibly originally stage 4)

Step 5. The medical record number for each patient was stripped from the
original file and placed into a separate password protected file. New columns
were added to match the variables that would be added based on chart reviews
(see Appendices 4, 5 and 7). A column was added to indicate when the data
collection was complete. Color coding was applied to indicate whether the data
came from the registry, electronic records or paper records. With the data
cleaning completed for the Tumor Registry data, the collection process from
electronic records and paper patient charts began.
Limited Data Set
A small subset of electronic records were chosen to practice the data collection
methods, learn the electronic medical record system and determine whether
paper charts were necessary. This limited data set exercise revealed several
challenges. First, around 30% of the records required paper charts to complete
the record. Second, some data in the registry was found to be erroneous, such
as a record showing that a recurrence had occurred, when in actuality there
never was a recurrence at all. Last and importantly, I learned that some of my
preconceived operational definitions would not handle all situations. In some
cases, there was variation between lab reports and doctors’ notes (to be
discussed later) and a judgement had to be made on how to code the data and
whether to use it in the analysis. Therefore, I decided to review those cases with
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the Tumor Registry manager and adhered to her interpretation which she based
on industry standards.
Finalizing the Data
The data collection process was slow and arduous. I double-checked records
with the Tumor Registry manager to ensure quality and found that access to
paper charts (when needed) was somewhat limited, since many reviews dated
back to the year 2000 and most patients in this study were now deceased. The
physicians’ offices most closely associated with the Cancer Center and with the
longest tenure were able to provide many of the charts I needed. Charts from
private practice physicians or with patients pre-dating their association with UT
were harder to obtain. While I did not get access to all the data in the patient
population set, I was confident that the data I did obtain was a representative
sample of that population, even though my sample was not a statistically
designed random sample. The data collection progression is described in Table
17. The key activities for each step data collection are documented below.

Table 17. Data Collection Files

Step
1
2
3
4
5

Excel File Name
1.521 Breast Recurs
START
1.55 Breast Recurs
START
1.60 Breast Recurs
START
1.742 Breast Recurs
START
1.82 Breast Recurs
FINAL
Totals (586 records)

Records
to
Exclude

Records
with
Data not
Useable

Records
that
Remain
to
Review

32

0

11

543

66

98

74

305

13
No Change
(NC)

171

74

37

NC

NC

NC

3

0

34

0

124

269

193

N/A

Number
of
Complete
Records
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Step 1. The initial collection of data in the limited data set yielded 32 completed
records and 11 unusable records. Unusable records fell into three categories: a)
insufficient data, when the electronic record was woefully incomplete and the
prospect of obtaining the paper chart was not deemed plausible; b) no evidence
of recurrence, where a thorough review of the electronic records did not confirm
a metastatic recurrence; and c) not applicable, in cases where cancers other
than breast cancer presented, stage 4 was diagnosed initially, or men were
included the data set.

Step 2. Several groupings of records were identified in the data that had similar
characteristics. Records in these groups were eliminated, where as a group,
there was a very low probability of obtaining complete and useful data. My
decision to eliminate groups of records was based on a sample review of the
group records. Seventy-four records were eliminated based on the analysis of
these groups. Additionally, 98 total records were excluded where: a) 33 had a
filler recurrence date of 11/11/11 and the last contact was before the year 2000;
b) 42 had no recurrence data and last contact before the year 2000; and c) 23
had a filler recurrence date of 11/11/11, the patient was deceased, and the
record did not fit the protocol of this study.

Step 3. One hundred and seventy-one records were excluded because a
sampling of those records showed either no evidence of recurrence or insufficient
data. The excluded records contained: a) 50 records with a recurrence date of
11/11/11 and the patient was listed as alive; b) 34 records that had a no
recurrence date and the patient was listed as alive; and c) 87 records containing
no recurrence date and no other data indicating a recurrence. This extensive
effort produced only 13 useable records. The 37 remaining records required that
I request paper copies of the patients’ records.
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Step 4. Columns with extensive missing values and un-needed columns were
removed. New variables that were a combination of columns, like subtracting
two dates, were created. Data in the spreadsheet was compared with the data
collection sheets for an additional quality control check.

Step 5. Completion of the data record was possible for only three of the 37
remaining records. The other 34 were unusable because of insufficient data.
Data Collection Summary
The final dataset was named 1.9 Breast Recurs FINAL. The breakdown of the
124 records in the completed dataset is illustrated in Figure 16 for each cohort of
the study. As noted in Figure 16, 14 of 92 (15%) patients had discordant

Figure 16. Actual Sample Sizes
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receptor statuses. This sample result was slightly lower than the 20% I
expected, but not out of line given that my definition of discordant was more
restrictive than all but two of the relevant articles cited in the literature review.
Of the 14 patients whose results were discordant, eight patients had their firstline treatment plan based on their primary tumor receptor status and six
patients’ treatment was based on the metastatic tumor receptor status. The
sample result of 6 of 14 (43%) patients with a first-line treatment plan based on
the metastatic tumor receptor status was lower than the 60% to 75% I
estimated using data found in the current literature as discussed in Chapter 2.
One reason for this discrepancy could have been the nature of variation in
sample percentages estimated with small sample sizes. Additionally, my 60% to
75% estimate was based on current practices, while my data represented
records evaluated over a 15 year period.
List of Variables in the Final Dataset
The list of variables utilized in the final dataset, the available source(s) of the
data for each variable, and the purpose for each variable is shown in Appendix 7.
Appendix 8 contains a list of variables maintained in the dataset for information
purposes only, and not utilized in any analysis.
Preparing the Data for Analysis
Once the final Excel spreadsheet was complete, the data was moved to a JMP
file for final processing and analysis. Histograms of all key variables were made
as a visual quality check that ensured correct data entry and assessed the data
for outliers. No outlier was revealed. Table 18 compares the number of valid
variable responses against the total sample size available (n of N). Four records
in the discordant cohort presented coding challenges when the records were
investigated. That is, there were difficulties applying the a priori operational
definitions to the actual data, such that alternative evaluations of the
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Table 18. Sample Size Completeness

Variable Name
PRS
Status
FSD
Rdate
Retested
mPheno
pPheno
FLTP
FLD
LocoRegion
Visceral
rLocation
RECIST
Age
TTR
pER
pPR
pHER2
SSS
Hormone
Chemo
Rad
Herceptin
Grade
Size
nPos
AJCC
Type Chemo

(n of N)
124 of 124
124 of 124
124 of 124
124 of 124
124 of 124
14 of 14
121 of 124
14 of 14
13 of 14
117 of 124
116 of 124
84 of 124
14 of 14
124 of 124
124 of 124
119 0f 124
119 of 124
107 of 124
78 of 124
114 of 123
118 of 123
121 of 124
102 of 124
110 of 124
120 of 124
121 of 124
123 of 124
113 of 124
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values of key variables were possible. Those records and the challenges are
outlined in Table 19. Those four records were first analyzed as they were coded
with my best effort to apply the a priori definitions. In order to ensure an
unbiased evaluation, a sensitivity analysis was performed based on these four
data points. This sensitivity analysis was accomplished by changing the coding
interpretation of those four records such that those records were not supportive
of my hypothesis and then conducting the data analysis. Next, those four records
were changed such that the coding interpretation was supportive of my
hypothesis and reanalyzed. Those results are reported later in this section.

Table 19. Sensitivity Analysis Records

ID
Code
103
188
312
558

Best
Judgement
Coding
Concordant
Discordant,
Metastatic
Discordant,
Primary
Discordant,
Metastatic

Not Support

Support

Coding
Discordant,
Metastatic

Coding
Discordant,
Primary

As is

Concordant

Concordant

As is

Discordant,
Primary

As Is

For the patient with ID code 103, the primary tumor was ER and PR negative.
The metastatic ER and PR test results were 1% and 5% respectively. Historically,
these values were interpreted as negative, but standards have changed over
time such that these results would currently be deemed positive. The physician
noted the results were weak in the patient chart. He prescribed chemotherapy as
the first-line treatment plan and then switched to endocrine therapy, even
though the chemo was working. In my judgement, this change in therapy was
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planned ahead of time and not based on a patient assessment; however I was
unable to verify my assumption. The record would have be coded concordant
based on the lab report. The record would have been coded discordant based on
the physician’s interpretation. If I assume the physician’s original plan was to
switch to endocrine therapy, then the treatment plan was based on the primary
tumor. If I assumed the switch occurred because of a clinical judgement after
assessing the patient’s progress, then the original plan would have been coded
as based on the metastatic tumor receptor status.
The primary tumor in patient ID code 180 was reported equivocal at 2+ on
HER2. General practice indicated an equivocal result as HER2-; however the
patient received Herceptin per the doctor’s orders, which indicated a HER+
judgement ("Breast Cancer," 2015, pp. 36-37). The metastatic tumor was TNBC,
and Herceptin was not prescribed for treatment.
Her2 in the primary tumor for patient ID code 312 was measured as negative.
Her2 in the metastatic tumor was measured as 2+, which is judged equivocal by
current practices and requires an alternate test to confirm the results. The lab
report called the metastatic result positive and noted that the tumor sample was
not large enough to perform the alternate test.
Patient ID code 558 was ER/PR positive in her primary tumor. The recurrent
tumor was TNBC. I was not able to review this chart, but the Tumor Registry
manager did and indicated that endocrine therapy was not utilized upon
recurrence. The lack of endocrine therapy indicated the treatment was based on
the metastatic tumor. Given that I did not review the chart myself, and that the
possibility existed that the patient was already on endocrine therapy at
recurrence, I included this patient in the sensitivity analysis. Key variables for all
the discordant patients are in Appendix 9, Table 26.
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Comment on Sample Size
The final sample size of 14 discordant cases was disappointing, and on the lower
end of the range I believed I would find a priori. Previous discussions in Chapter
3 on statistical power addressed the desired sample sizes for this study. I
compare the sample size of 14 to sample sizes in the literature review in Table
20. These values are sample sizes for five key papers referenced in this
dissertation and include two of the most cited articles in my review. In these
papers, the primary statistical comparison the authors make is comparing
concordant versus discordant patients (last column in Table 20). However, my
hypothesis required a further breakdown of the discordant data into two parts
(based on the first-line treatment plan), thus further reducing sample size of the
two groups that were statistically compared. While my sample was small (n=14
discordant cases), it was consistent with sample sizes found in the literature.

Table 20. Sample Size Examples

Number
of
Citations

Total
Sample
Size of
Interest

Sample Sizes
of Relevant Discordant
Group
Sample
Comparisons
Size

Author
Niikura(Niikura
106a
182
139,43
et al., 2012)
Liedtke(Liedtke
127
231
134,42,22,33
et al., 2009)
Simmons(Simmo
126
29
11,3
ns et al., 2009)
Wilking(Wilking
49
151
136,15
et al., 2011)
Chang(Chang et
15
56
42,14
al., 2011)
anoted as a “Highly Cited Paper” on Web of Science.
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43
22
14
15
14

Study Results

Fourteen records were found to be discordant, with eight patients treated in the
metastatic setting based on their primary tumor status and six patients treated
based on their metastatic tumor status. The survival data for these 14 patients
was consistent with my hypothesis that patients with treatment plans based on
the primary tumor receptor status have a longer median life expectancy.
Kaplan-Meier Survival Analysis
The Kaplan-Meier method was used as the primary tool to understand and
compare survival curves. This method is a common technique in survival analysis
and employed extensively in the articles reviewed for this dissertation (Richard
Van Noorden & Brendan Maher, 2014). All p-values quoted for survival analyses
were from the log rank test utilizing JMP 10.0 Pro.
Overall survival. Survival curves for metastatic breast cancer patients are
difficult to find in the literature due to the fact that patients diagnosed with
metastatic breast cancer are not tracked by the national databases. Although
estimating a survival curve for patients with metastatic breast cancer was not
one of the objectives of this analysis, a survival curve determination was
important for context and for the cancer community as a whole, given the limited
available data. The overall survival curve provided in Figure 17 represents all the
complete records in the dataset (n=124). It shows a median survival time of 18
months and a five year survival rate of just over 20%. These numbers were
consistent with the limited data available (CTCA, 2014). Additionally, I analyzed
the difference between those patients who had their receptors re-tested and
those who did not. My a priori assumption was that patients diagnosed to be in a
“worse” condition might get their receptors re-tested in an effort to find a better
treatment plan. Thus, those re-tested would have a shorter survival than those
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Figure 17. Overall Survival Curve
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not re-tested. This assumption proved to be erroneous and the opposite result
occurred as shown in Figure 18. While the literature review led me to believe
that around 50% to 70% of patients may be re-tested based on current
standards and less than 50% in the early 2000’s, at the University of Tennessee
Cancer Center it was a common practice to re-test throughout those years. In
most cases where the patient was not re-tested, the patient presented in such a
dire situation that there either was no time to re-test or it was deemed too late
for any treatment to succeed. Thus, those not re-tested (median survival of
about 5 months) showed a much worse outcome than those who were re-tested
(median survival of nearly 24 months). The two survival curves re-tested (Yes)
versus not re-tested (No) were evaluated for equality using the log rank method.
The result of the test indicated the two curves did not have the same survival
rate; therefore I rejected the null hypothesis of equality, with a p-value of .0002.

Figure 18. Re-test versus Not Re-tested Survival Curve
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In order to judge discordance for a metastatic patient, the patient must be retested. Therefore, all remaining analyses were performed on patients who were
re-tested, with the exception of one multivariate analysis performed on the
complete data set.
Discordance survival. As discussed in the literature review, the survival
outcome of patients with discordant receptor results tended to be less favorable
than those with concordant results. However, in my data set, the results indicate
the two groups had similar survival curves. That is, the null hypothesis that the
two curves were the same was not rejected (p-value = .986). These results are
shown in Figure 19. Sample size limitations (only 14 discordant cases) and the
fact that only 6 of 14 (43%) patients had their treatment plan based on the
metastatic tumor receptor status reasonably explained the results of similar
survival curves. In Chapter 2, I estimated that 60% to 75% of patients had their
treatment plans determined based on the metastatic tumor receptor status; my
sample results proved to be lower than this, which yielded more patients in the

Figure 19. Concordant versus Discordant Survival Curves
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discordant sample that performed well based on their treatment plans being
determined by their primary tumor receptor status.
Treatment strategy survival. The primary purpose of this study was to
compare the clinical outcomes of patients with discordant results on the basis of
whether their primary or metastatic tumor receptor status was utilized to develop
their first-line treatment plan. Figure 20 shows the results of this comparison.
The graph clearly indicats that those patients whose first-line treatment plan was
based on the receptor status of the primary tumor (n=8) had better survival
outcomes than those who had their plans based on the metastatic tumor (n=6)

Figure 20. Metastatic Versus Primary

with a p-value of .049. The statistical results showed that metastatic breast
cancer (MBC) patients who were treated based on the receptor status of their
primary tumor had a median survival time of 48 months versus only eight
months for those patients whose treatment plan was based on the metastatic
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receptor status. This sample result of a 40 month difference in life expectancy
was consistent with the important article by Liedtke et al. (2009) in the literature
review and exceeded my qualitative a priori estimate of 12 months. Given the
small sample size, other limitations discussed in Chapter 5 and the general poor
prognosis of MBC patients, I would hypothesize the effect of utilizing the primary
tumor receptor status to determine first-line treatment plans will likely be closer
to 12 months than 40 months when larger samples sizes are studied. Regardless
of the exact number, this finding provides a significant increase in life expectancy
for metastatic breast cancer patients. Given the small sample size, and other
limitations listed in Chapter 5, I described my results as consistent with my
hypothesis rather than utilize the a priori decision that stated the results support
my hypothesis when a p-value less than .05 was found.
Chi-Square Analysis (RECIST Standard)
Figure 21 shows the breakdown of discordant patients based on the RECIST
standard and whether their treatment plan was based on their primary or

Figure 21. RECIST Chi Square Analysis
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metastatic tumor receptor status. In chapter 3, I defined the RECIST standard
and the intention to utilize that standard to code the results of the first follow-up
examination performed by the patients’ doctor, which occurs approximately 90
days after treatment begins for the metastatic disease. This metric was
developed as a means to measure the immediate effect of the first-line
treatment plan, since numerous plans might be implemented before the patient
died, as all treatments lose efficacy over time. Based on the small sample size, I
expected the Chi-Square analysis on the RECIST standard would not be
statistically significant, and it was not with a p-value = .164 using Fisher’s exact
test for contingency tables. However, the results were consistent with my
hypothesis, given that a) of the five patients who had progressive disease (PD)
at the first re-scan, four were treated based on their metastatic tumor receptors;
b) five of the seven patients with stable disease (SD) were treated based on their
primary tumor; and c) the only patient with a partial response (PR) was treated
based on their primary tumor receptor status.

Multivariate Analysis

My statistical results were consistent with my hypothesis that metastatic patients
with discordant receptor results whose first-line treatment plans utilize the
primary tumor receptor status instead of the metastatic status had increased
median life expectancy. To further substantiate these results, it was necessary to
detect any covariates that might impact or influence the observed sample life
expectancy. To examine the impact of covariates, the Cox Proportional Hazards
method was used to analyze the data. Multivariate statistical analysis requires
relatively larger sample sizes than univariate analyses. The number of variables
that can be analyzed at once is strictly limited by the number of observations and
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further impacted by nominal variables with multiple levels. Due to the small
sample size of patients with discordant results in my study, effective multivariate
analysis was not feasible on that subset of my data. Only a few variables could
be tested at one time and the results were unlikely to be statistically significant. I
employed various analyses with a small number of variables and verified the
small sample size did not lead to statistically significant results. To determine
whether potential covariates could impact the survival of patients and potentially
bias the univariate results, I utilized the complete dataset and the re-tested
patients to investigate the covariates. These findings are discussed below and in
the Limitation section in Chapter 5.
Complete Dataset Results
The covariates available for analysis (referenced in Chapter 3) were utilized in a
Cox regression analysis. Due to the relatively small sample size and the high
number of nominal variables, I did not attempt to test any interactions between
available covariates, only main effects were tested on the variables. The results
of the initial analysis are shown in Appendix 10, Figure 33. The final model
utilized is shown in Figure 22. This model was based on several iterations of the

Figure 22. Whole Dataset Final Results
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analysis where any variable with a p-value of .2 or less was initially kept in the
model. Fourteen variables were found to be statistically significant with a p-value
of .20 or less in the initial analysis. The 14 significant variables were iteratively
re-analyzed, removing variables with a p-value greater than .10, and the final
results indicated that six variables (Grade, Size, nPos, Chemo, pPheno, Retested)
were statistically significant with a p-value of .10 or less. I kept variables with pvalues less than .1 as a conservative measure to ensure I identified any
covariates that could potentially impact the survival time of patients. For
demonstration purposes, the graphical illustration of the effect of the variable
pPheno, the receptor status of the primary tumor, on survival time is shown in
Figure 23. The key point to note is that TNBC patients perform more poorly
(shorter survival time) than do the other three phenotypes. It was important to
review the breakdown of TNBC patients in my discordant sample, noting whether
treatment were plans based on the primary tumor versus the metastatic tumor.

Figure 23. pPheno KM Analysis
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If, for instance, there were significantly more patients in the metastatic tumor
group who were TNBC than in the primary tumor group, a potential explanation
for the differences between the groups would be the effect of the variable
pPheno, rather than the impact the first-line treatment plan determination being
based on the receptor status of the metastatic or primary tumor. This point is
further explored in the Univariate Statistical Analysis section of this chapter.
Multivariate Results for Re-Tested Patients
A previous analysis indicated that those patients whose metastatic tumors were
re-tested had better survival outcomes than those patients not re-tested.
Therefore, I conducted a multivariate analysis on the re-tested patients. Utilizing
the Cox regression analysis on the re-tested patients, I employed the same
procedure I used on the complete dataset. The final results of the analysis is
shown in Figure 24. These results showed three of the six variables that were
deemed statistically significant in the complete dataset, were also significant in
the re-tested dataset. Additionally, two variables (Herceptin, LocoRegion) were

Figure 24. Multivariate Results for Re-Tested Patients
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Statistically significant, yielding a total of eight variables identified as covariates
that impacted patient survival and could potentially bias the univariate analysis
performed on the discordant data. These eight variables warranted further
univariate analysis.

Univariate Statistical Analysis

A two-sample univariate analysis was performed on each available covariate for
the 14 discordant patients. Each analysis tested whether there were statistically
significant differences between the subset of patients who had their treatment
plan based on their primary tumor receptor status (n=8) and those who had
treatment plans based on the metastatic tumor (n=6). For continuous variables,
a two sample t-test was performed on the sample averages. For nominal
variables, the exact Fisher test for contingency tables was used to test the
equality of the percentage of patients in each nominal category. The analysis
results are listed in Table 21. The eight covariates found in the multivariate
analysis to be statistically significant are indicated with and asterisk. Given the
small combined sample size of 14, the fact that no results were statistically
significant was not unexpected.
To be thorough in the examination of the covariates, I reviewed the numerical
differences between the two cohorts in spite of the lack of statistical significance
for any variable. From a purely numerical standpoint, there was very little
difference between the two samples for all but one covariate. For instance, the
age at diagnosis for each sample differed numerically by only .2 years.
Additionally, neither of the two cohorts had patients with TNBC primary tumors.
Given that the multivariate analysis demonstrated that patients with TNBC
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Table 21. Univariate Analysis

First-line
First-line
Treatment
Treatment Based
Based on
on Metastatic
Primary Tumor
Statistical
Tumor Receptors
Receptors
Significance
Variable
(n=6)
(P-value)
(n=8)
Age
56.1
55.3
.890
TTR
1596.5
1390.9
.729
Grade*
2.6
2.6
.935
Size*
35.8
27.0
.463
nPos*
7.0
8.0
.832
Age DX
51.7
51.5
.975
Her2+(1), HR+(2), Her2+(1), HR+(6),
pPheno*
PBC(3), TNBC(0)
PBC(1), TNBC(0)
.450
Her2+(1), HR+(1), Her2+(0), HR+(1),
mPheno
PBC(0), TNBC(4)
PBC(2), TNBC(5)
.723
AJCC Simple
S1(0), S2(3), S3(3) S1(2), S2(3),S3(3)
.600
Distant(6),
Distant(6),
LocoRegion*
Regional(0)
Regional(2)
.473
Visceral
Non(0), Visceral(6) Non(4), Visceral(4)
.085
Hormone
Yes(3), No(3)
Yes(4), No(3)
.999
Chemo*
Yes(5), No(1)
Yes(5), No(3)
.580
Rad
Yes(5), No(1)
Yes(5), No(3)
.580
Herceptin*
Yes(4), No(1)
Yes(2), No(5)
.242
*Variables found statistically significant in one of the multivariate analyses.
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primary tumors had shorter life expectancies, had the two cohorts contained a
different number of TNBC patients there would have been cause for concern
about a possible bias in the survival analysis. The one variable that did present
some concern was Visceral. The Visceral variable is an indication of the location
of the metastatic tumors. Visceral tumors are located in essential organs such as
the lung, liver or brain. Non-visceral tumors are generally located in the bones
and lymphatic system. All patients whose treatment plans were based on their
metastatic tumor receptor status had metastatic tumors rated as visceral, while
only 4 of 8 patients whose first-line treatment plan was based on their primary
tumor were rated as visceral. Visceral and metastatic treatment plan were thus
statistically confounded in this study. Figure 25 shows she KM survival analysis
curve

Figure 25. Visceral versus Non-Visceral
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comparing visceral and non-visceral patients. The curves indicated that visceral
patients performed worse (about 6 months shorter median PRS) than the nonvisceral patients, although this result was not statistically significant with a pvalue of .210. I made two evaluations of the impact the variable Visceral had on
the primary versus metastatic tumor comparison results. First, I performed a Cox
regression analysis on the discordant patients with the variable FLD (whether the
primary or metastatic tumor receptor status was used to determine the first-line
treatment plan) and Visceral in the model. The analysis results indicated that
Visceral is not statistically significant and that even with Visceral in the model,
FLD still had a hazard ratio of 4.2. These results are shown in Figure 26. This
analysis indicated that patients whose first-line treatment plans were based on
their metastatic tumor were 4.2 times more likely to die at a given point in time
than those patients whose plans were based upon the primary tumor, even after
accounting for the effect of the variable Visceral. Second, I performed a KM

Figure 26. Cox Regression with Visceral
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survival analysis on the discordant patients with only the visceral cases, which
removed four of the patients whose first-line treatment plans were based on
their primary tumor receptor status. These results are shown in Figure 27. The
numerical and graphical results were nearly identical to the test results with the
non-visceral patients included in the analysis. Of course, with the smaller sample
size of 10 instead of 14, the p-value for the test of equal curves changed from
.049 to .152. While there was certainly a difference in the two groups being
compared based on the variable Visceral, I found no evidence that this fact was
biasing or influencing the conclusions of this dissertation. Based on the entirety
of the univariate analyses, I found no concern that a covariate biased the
conclusions of this dissertation.

Figure 27. Visceral Patients Only
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Sensitivity Analysis

As previously discussed, the four records in Table 19 represented data where the
interpretation of the records could have yielded different variable values and thus
impact the analysis of the discordant cases. I conducted two additional analyses
with this data; one where the data was coded with a reasonable interpretation of
the record such that the interpretation yielded data that was less supportive of
my hypothesis, and a second analysis where each record was interpreted such
that the coding resulted in data more supportive of my hypothesis. The analysis
in Figure 28 (best case) represents the data where those four records were
coded to support of my hypothesis. Obviously, the results showed a better
numerical difference compared to the results with the originally coded data, with
a best case median survival time of 42 months compared to the previously
discussed estimate of 40 months shown in Figure 20. This result was statistically
significant with a p-value of .0006.

Figure 28. Best Case Curves
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The analysis in Figure 29 (worst case) represents the data where the four
records were coded to not be supportive of my hypothesis. Understandably, the
results showed a worse numerical result compared to the originally coded data,
with a worst case median survival time of 22 months compared to the previously
discussed estimate of 40 months shown in Figure 20. These results were not
statistically significant with a p-value of .41.

Figure 29. Worst Case Curves
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CHAPTER 5
Conclusions and Recommendations

Conclusion

The purpose of this dissertation was to determine the impact on patient
outcomes in recurrent metastatic breast cancer diagnoses when the first-line
treatment plan was based on the receptor status of metastatic tumor(s) instead
of the receptor status of the primary tumor(s).
Restatement of Hypothesis

For discordant cases, if the first-line treatment plan is based on the receptor
status of the primary tumor, the median life expectancy of MBC patients will be
longer than MBC patients whose first-line treatment plan is based on the
receptor status of the metastatic tumor.
The weight of the evidence in this research is consistent with my hypothesis. The
evidence is supported by: a literature review of historical data that built a strong
case indicating that discordant MBC patients performed worse than concordant
patients; the log rank test results with a p-value of .049; the covariate analysis;
and the sensitivity analysis. A priori, based on the literature review, I expected a
minimum of a one year median increase in life expectancy for patients with
discordant receptor statuses whose first-line treatment plan was based on the
primary tumor’s receptor status instead of the metastatic receptor status.
Ultimately, the sample data showed that discordant MBC patients, whose firstline treatment plan was based on their primary tumor rather than their
metastatic tumor, had a longer median life expectancy of 40 months. The
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sensitivity analysis resulted in a worst case scenario of a 22 month median
difference, which still reinforces my hypothesis. Regardless of which life
expectancy estimate is theorized, 12, 22, or 40 months, my research provides a
distinct directive for determining first-line treatment plans for discordant MBC
patients. I proposed that if the data analysis supported my hypothesis this would
indicate a need for revised standards of care for MBC patients whose metastatic
tumor receptor statuses differed from that of the primary tumor.

Recommendation

Since 1989, the clinical impact of testing metastatic tumors for receptor status to
inform first-line treatment plans has been studied (Kamby et al., 1989). Prior to
my research, researchers had drawn no definitive conclusions regarding the
impact of re-testing receptor statuses on the clinical outcomes of metastatic
breast cancer patients. In Chapter 1, I stated the ultimate goal of this
dissertation was to influence changes in international and national standards
regarding the determination of first-line treatment plans in discordant cases of
MBC, and to provide a higher level of evidence for those standards.
Proposed Standard of Care
To assist physicians as they consult the relevant ABC2 and NCCN guidelines and
levels of evidence concerning the care of metastatic breast cancer patients with
discordant receptor statuses, I propose the implementation of the following overarching standard of care:

Where discordance between the primary and metastatic tumor receptor status
would indicate different treatments, the status of the primary tumor should take
precedent when developing the first-line treatment plan for a newly diagnosed
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recurrent metastatic breast cancer patient. Strong clinical evidence to the
contrary must be present to warrant basing the treatment plan on the metastatic
tumor receptor status.
Level of Evidence
The NCCN and ABC2 standards discussed in the Literature Review section of my
paper are not consistent with my research findings (Cardoso et al., 2014;
NCCN.org, 2014). As reported in Chapter 2, neither entity supports the standards
recommendations relevant to my hypothesis with citations from existing
literature. The ABC2 committee states their recommendation is based on expert
opinion only. Considering the ABC2 level of evidence definitions, I recommend
the level of evidence for my proposed standard of care be rated at 2B. Level 2B
is defined as “RCTs with important limitations or exceptionally strong evidence
from observational studies” and clinical implications of a “weak recommendation,
best action may differ depending on circumstances or patients’ or societal
values” (Cardoso et al., 2014, p. 2).

Research Limitations

Below I discuss five limitations of this research that could potentially impede the
application of my results to patient medical decisions. I then review how my
research design minimized or compensated for these limitations. While other
limitations may exist, I consider these five to be the most relevant.
Sample Size
My research sample size of discordant cases (n=14), included eight cases whose
treatment plan was determined by the primary tumor receptor status, and six
cases whose treatment plan was determined by the metastatic tumor receptor
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status. This sample size was statistically small, and it provided little statistical
power, as illustrated by the simulation results in Chapter 3. In addition to
statistical matters, practical concerns arose about the impact that data quality
could have on analyses, given that each record carried more weight in the
statistical calculations since the sample size was small. While my total sample
size (n=124) and the number of discordant cases (n=14) was small, such sample
sizes are common in the published literature and several heavily cited articles on
this topic (Table 20). For future studies, a larger sample size would be desirable
and may be obtained by including more and larger cancer centers.
Data Quality
Working with three sources of data, the tumor registry, electronic records and
paper patient charts, presented several data challenges. The most important
data quality challenge was that of applying operational definitions when
physicians utilized an interpretation of lab results that differed from the lab
report itself. Additionally, incomplete electronic records and lack of access to
paper charts diminished the available sample of patients. With a small sample
size, data quality was even more important since one or two inaccurate
observations could impact the analytical results and resultant conclusions. Data
quality issues and challengers were discussed in the Data Acquisition and
Sensitivity Analysis sections of Chapter 4. Understanding the importance of data
quality when working with small sample sizes meant that I needed to employ
safeguards as checks on data quality. I believe that the sensitivity analysis
performed provided protection against any data quality issues and thus limited
any impact on the accuracy of my results and conclusions. The best protection
against data quality issues was clear operational definitions, which I had, and
larger sample sizes, which I strongly recommend in future research.
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Inference Space
The fact that this study was performed at only one cancer center was a
limitation. Variation in cancer centers’ patient populations, policies and
procedures could potentially impact the ability to infer the results of my research
to other centers. While the results of my retrospective study are statistically most
valid for the population from which they were derived, I believe they can be
applied more widely from a practical standpoint. The fact that there have been
no clear standards of care regarding first-line treatment plans for MBC patients
with discordant receptor results created the opportunity to observe varied
strategies employed by the doctors at the UT Cancer Center. This variation,
based on doctor preferences, provides logical support for applying my results
beyond just one cancer center and one set of doctors. The best method for
ensuring a wider inference space for future research is to involve several cancer
centers in the protocol.
Limited Ability to Examine Covariates
In retrospective observational studies, it is important to evaluate the potential
effect of covariates on the research results. Such concern arises from the
researchers’ lack of ability to control important variables when a study is
retrospective rather than prospective. The importance of covariate analysis in the
specific research performed in this dissertation is reviewed by several authors
and discussed in the literature review (Dieci et al., 2012; Foukakis et al., 2012).
In my research, the sample size hindered my ability to establish the impact of
covariates on the results of this study. While I found no concerns for potential
biasing of results based on the covariate analysis discussed in Chapter 4, it
remains possible that confounding effects exist that bias the analysis results.
Again, a larger sample size would help alleviate this limitation in future research.
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Researcher Bias
Creswell (2009), suggests researchers clarify through self-reflection any potential
for researcher bias in the design and implementation of their research projects
(p. 192). As the researcher for this dissertation, I certainly had an emotional
attachment to my hypothesis, given that it was motivated as a result of my wife’s
death. To avoid any bias or appearance of bias on my part, I applied various
protections in the design and implementation of my research. The design of this
research was reviewed by two IRB boards and my dissertation committee that
had a practicing research oncologist as a member. Given the research design
was fully vetted, the remaining potential for researcher bias was in the collection
and analysis of the data. To eliminate bias in the analysis phase, the analysis
plans and standards were established a priori. These plans and standards were
ultimately implemented as the research design indicated.
My initial idea for removing potential researcher bias in the data collection phase
was to have someone else collect the data, such as a medical resident. My
committee chair and the oncologist member of my committee both
recommended that I collect the data myself for two reasons: First, relying on
someone else would mean the length of data collection time was out of my
control. Second, the committee members believed collecting my own data
provided an important learning experience, since I had never before collected
medical data. Once the decision was made that I would collect the data, I
developed three strategies to protect against potential data collection researcher
bias. I first created detailed operational definitions of each data variable in an
attempt to eliminate the need for judgement calls when evaluating patient
records. Next, my quality review process involved an independent expert, the
Tumor Registry manager, who reviewed all the discordant cases and other
samplings of records. Lastly, I meticulously documented every step of the data
acquisition, cleaning and collection process. My records allow an independent
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observer to retrace any of my data records to the original patient records or to
track any patient ID to the documented and analyzed data.
The advice of the committee members to collect my own data proved invaluable.
Because of the complexity of the data collection process, I believe an
independent person, not immersed in the topic of this research endeavor, could
not have completed the collection process without being in constant consultation
with me, thus clouding the intended independence. The discovery, outlined in
Chapter 4, that those patients who did not have their metastatic tumor receptor
status re-tested performed poorly, was a surprising and important finding.
Because I personally conducted the record reviews, I was able to discern that in
most cases where the patient was not re-tested, the patient had presented in
such a dire situation that there either was no time to re-test or it was deemed
too late for any treatment to succeed. An independent data collector would have
likely missed this subtlety in the medical records since this information was not
part of the pre-planned data collection process. Had I not collected the data
myself, the interpretation of this one aspect of the data would have added an
additional limitation to my results.

Contribution
At the time of completing this dissertation, I was unaware of any published
scholarly paper or unpublished work that had expressly addressed the clinical
impact of utilizing the metastatic receptor status of patients to determine their
first-line treatment plan. For over 20 years, researchers have studied issues
related to this topic; however, the precise question I examined in this
dissertation was never evaluated. For the first time, the clinical impact of utilizing
the receptor status of metastatic tumors, when determining MBC patients’ first101

line treatment plan has been studied and reported. Additionally, my stated goal
has always been to impact the national and international standards of care for
discordant MBC patients. Proposing the over-arching standard recommending
medical decisions for discordant MBC patients focus on the receptor status of the
primary tumor and upgrading the level of evidence for that standard to 2B is a
further contribution of my research. My intent is that this research leads to
physicians consulting and implementing the over-arching standard of care I
proposed, thus extending the lives of MBC patients.

Future Research

The primary need for future research is the engagement of additional cancer
centers to utilize the protocols of this study to increase the sample size of data
specifically targeting my hypothesis and expand the inference space for
implementing the conclusions I have reached. Since the current medical
standards on the appropriate treatment plan for discordant cases of recurrent
metastatic cancer are weak, it would be beneficial to have data from various
cancer centers that perhaps utilize different criteria about re-testing receptors
and how that data is used to determine treatment plans. For example, in my
personal experience with my wife and consulting the oncologist on my
committee, I encountered three cancer centers (Piedmont in Atlanta, MD
Anderson in Houston, and UT Knoxville) with at least three different approaches
to determining first-line treatment plans. At one center, I witnessed a physician
who did not make it a practice of re-testing the metastatic receptors to
determine the first-line treatment plan. At a second center, the physician’s
standard practice was to re-test and utilize the results of that test to assist in
treatment decisions. At the third center, there was no written standard; there
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was a general practice of re-testing when possible, and each doctor then decided
independently how to utilize the information on the metastatic tumor receptor
status. I see two paths for expanding the number of cancer centers involved in
my research. First, I will seek to engage other researchers, identified through my
literature review, who have studied the impact of discordant receptor statuses.
Based on my review, I believe some authors already have the data available
from previous research to implement the analysis on cohorts E and F of my
study. Other authors would need to add a new variable to their existing data
identifying whether the first-line treatment plan was based on the primary or
metastatic tumor receptor status. That additional variable would allow the
researcher to determine the impact of the first-line treatment plan decisions.
Second, I will seek to engage other cancer centers to grant me access to their
data. With additional patients from different cancer centers, the amount of data
would mount and contribute to an even higher level of evidence to inform the
determination of first-line treatment plans for MBC patients with discordant
tumor receptor statuses.
Unanswered Question
One unexplored question in my research and in the literature is: Why does

determining first-line treatment plans based on the primary tumor receptor
status, as opposed to the metastatic tumor, result in better patient outcomes?
The only answer proposed in the literature is measurement error. Liedtke et al.
(2009), provides a good discussion of the potential impact of measurement error
in the testing of MBC patients metastatic tumor receptor status. My belief is that
measurement error is certainly part of the explanation, but to what extent is
unknown. Presently I am content to know what the right decision is without
having to understand why that decision is the correct one. If others wish to
investigate this question, then that knowledge may lead to enhancements in the
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first-line treatment plan decision making process and an increased understanding
of the metastatic disease.
Definition of Discordance
One of the challenges during my literature review was that several definitions of
discordance were utilized by researchers. I provided a clear and logical definition
for discordance in Chapter 3. From a scientific point of view, having a universally
applied definition of discordance is important. Such a definition would promote
better research designs, produce clearer analyses, allow for more effective
comparisons across studies and enable quantitative meta-analyses to be
performed.

Impact

In September of 2013, Amy Foster was given four years to live. She died four
months later after her treatment plan was modified based on the discordant
receptor status of her metastatic tumor. As discussed in chapter 1, an estimated
60,000 women per year world-wide are faced with a decision because their test
results show discordant receptor statuses. For the majority of those women,
their first-line treatment plan will be based on their metastatic tumor and they
will suffer the consequence of a shortened median life expectancy of one to
three years. It is my hope that this dissertation will help affect a change in the
standards of care for women with discordant receptor statuses. With the data I
have, I will personally recommend to anyone faced with this particular medical
decision to base their first-line treatment plan on the primary tumor receptor
status. As new and better data is developed, then the level of evidence can be
raised and the relevant standards updated appropriately. Cardoso (2009), calls
metastatic breast cancer patients the forgotten heroes because today’s breast
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cancer research focuses on early detection and treatment of primary tumor
breast cancer, not on challenges and issues facing metastatic patients. She
laments, and I agree, “it is clearly a time for change!” (Cardoso, 2009, p. 271).
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Appendix 1: List of Abbreviations
Table 22. Appendix 1- List of Abbreviations

Abbreviation
ABC1
ABC2
ER
HER2
HER2+
HR+
LDS
LoE
MBC
MDA
NCCN
OS
PBC
PR
PRS
SAS
TNBC
KM
HR
PHI
AJCC

Definition
First International Advanced Breast Cancer Conference
Second International Advanced Breast Cancer Conference
Estrogen Receptor status
Human Epidermal growth factor Receptor 2
HER2 positive. HR Negative
Hormone receptor positive (ER and/or PR positive), and
Limited Data Set
Level of Evidence
Metastatic Breast Cancer
M.D. Anderson Medical Center
National Comprehensive Cancer Network®
Overall Survival
Positive Breast Cancer (HR+ and HER2+)
Progesterone Receptor status
Post Recurrence Survival
Statistical Analysis System (statistical software)
Triple Negative Breast Cancer
Kaplan-Meier Survival analysis method
Hazard Ratio
Protected Health Information
American Joint Committee on Cancer
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Appendix 2: Incidence Rate
Table 23. Appendix - Seer Breast Cancer Incidence Rates

Year of
Diagnosis

All Races, Females,
All Ages

Deaths All

1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011

105.07
101.92
100.82
100.64
102.14
102.26
106.37
106.5
111.15
116
124.26
126.86
134.5
131.33
127.22
131.86
133.85
132.05
129.22
131
132.63
133.7
137.99
141.39
141.46
136.48
138.76
135.73
126.92
128.03
126.51
126.14
128.06
128.11
130.52
126.46
129.56

31.45
31.8
32.48
31.73
31.21
31.68
31.92
32.19
32.07
32.9
32.98
32.87
32.66
33.2
33.23
33.14
32.69
31.64
31.39
30.92
30.55
29.49
28.21
27.54
26.61
26.64
26.01
25.62
25.27
24.49
24.14
23.56
22.96
22.55
22.24
21.92
21.54
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Appendix 3: Permissions

Periodical Permissions

Figure 30. Periodical Permissions

NCCN Permission
NCCN allows students to utilize NCCN content without specific permission. The
NCCN website states “Students using NCCN content in academic thesis or
presentations for research purposes do not require written permission from
NCCN. However, a credit line acknowledging NCCN, the name of the NCCN
Guideline, and NCCN's website (www.nccn.org) should be included”(NCCN.org).

Appendix 4: Operational Definitions
1. Recurrence date
a. Earliest known date of;
i. Symptom occurrence that led to doctor visit
ii. Date of doctor visit where indications of metastatic disease
are identified
iii. Date of confirmation of metastatic disease
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2. Description
a. Loco-regional
b. Distant
c. Non-visceral
d. Visceral
e. Visceral Crisis
3. Receptors Retested? Reason Codes
a. A- No, Not feasible/safe
b. B- No, Standard practice
c. C- No, No indication of need
d. D- Yes, Primary results missing, old or suspect
e. E- Yes, Standard practice
f. F- Yes, Clinical indications
Result – as interpreted by the doctor
Location of biopsy? Tissue, location
4. Results Concordant? By 4 phenotype definition
a. TNBC : Triple Negative Breast Cancer
b. HR+ : Hormone receptor positive (ER and/or PR positive), and
HER2 negative
c. HER2+ : HER2/neu positive. HR Negative
d. PBC: Positive Breast Cancer HR positive and HER2 positive
Primary
5. First-Line Treatment Plan based on?
Metastatic
- By doctor notes preferably. By doctor interview. By comparing
receptor status with NCCN guidelines if necessary.
a. Why?
i. A- Standard Practice
ii. B- Doctor preference
iii. C- Clinical indications
iv. D- Primary results missing, old or suspect
v. E- Other
6. First Line Treatment?
a. A- Chemotherapy
b. B- Endocrine Therapy
c. C- Targeted Therapy
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d. D- Chemo + Targeted
e. E- Other
7. First Reassessment Result (RECIST criteria)
a. D – Deceased
b. CR- Complete Response – Signifies that all target lesions have
disappeared during the course of treatment.
c. PR- Partial Response - Signifies that decreases of at least 30%
have been noted in the lesion that has the largest diameter (LD)
d. SD- Stable Disease – Signifies that there has been no significant
decrease or increase in the size of target lesions
e. PD- Progressive Disease – Signifies that there has been an increase
of at least 20% in the sum of the LD of targeted lesions
8. Date Deceased or Last Contact
a. Last contact verifying the whether the patient was alive or
deceased. Could be a phone call, email or doctor’s visit.
b. Where doubt, obituary records may be searched
c. Patients will not be contacted for this information for this study
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Appendix 5: Data Collection Sheet

Figure 31. Data Collection Sheet
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Appendix 6: Data Breakdown Flowchart

Figure 32. Data Breakdown Flowchart
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Appendix 7: Variables Utilized
Table 24. List of Variables Utilized

Variable
Name

Description

PRS

Post Recurrence
Survival – the length
of time after the
patient was
diagnosed with a
recurrence until
death or last contact

Status

The final Status of
the patient at last
contact

FSD

Rdate

Source
Most of this data
is from the
Tumor Registry.
The data was
validated and
updated if
necessary during
the data
collection process
Most of this data
is from the
Tumor Registry.
The data was
validated and
updated if
necessary during
the data
collection process

Final Status Date –
the date of last
contact or death
Recur Date – The
date the metastatic
recurrence was
validated

Comment
This is the main
metric of the
study. It is
measured in days
and will be
graphically
reported in years

0= Deceased
1= Alive at last
contact

Same as above

Same as above

Retested

Was the metastatic
tumor(s) retested for
the receptor status?

mPheno

Phenotype of the
metastatic tumor
when retested

pPheno

Phenotype of the
primary tumor when
retested

Found in the
patient records.
Assumed “No” if
no evidence.

Yes/No

Found in the
patient records

Found in either a
lab report or
doctors’ notes or
both.

Found in the
patient records
and/or the tumor
registry
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Cross-checked if
found in both
sources

Table 24. List of Variables Utilized, Continued

Variable
Name

Concordant

FLTP

FLD

LocoRegion

Visceral

rLocation

RECIST

Description
Where Retested =
“Yes”, do the primary
and metastatic tumor
receptor statuses
match?
First-line Treatment
Plan. Only
determined for
discordant results.
First-line Decision –
Was the first-line
treatment plan based
on the metastatic or
primary tumor. Only
determined for
discordant results.
Is/are the metastatic
tumor(s) local to the
breast, distant or
both?
Based on the extent
of the disease and
the condition of the
patient
Where in the body
are metastatic
tumors located?
The patient status at
their first post
treatment evaluation,
usually around 3
months after
beginning treatment.
Only determined
for discordant
results.

Source

Comment

Found in the
patient records.

Does mPheno
match pPheno?
Yes/No.
No = Discordant

Found in patient
records

Coded per data
collection sheet in
Appendix 4

Found in patient
records.

Required
comparing the
plan to NCCN
standard
treatments by
phenotype to the
metastatic and
primary
phenotypes

Found in patient
records

Found in patient
records

Judgement call by
me

Found in patient
records

Found in doctors’
notes in patient
records
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This required
interpretation by
me. The patient
status using the
RECIST
terminology was
not used in the
doctors’ notes.

Table 24. List of Variables Utilized, Continued

Variable
Name

Age

TTR

pER

pPR

pHER2

Description

Source

Age at primary
diagnosis was
found in Tumor
Registry in whole
years.
Time to recurrence.
Found in Tumor
Calculated from
Registry, with
primary diagnosis
recurrence date
date and recurrence
verified in patient
diagnosis date
records
Found in the
Tumor Registry
and patient
Estrogen receptor
records. Most
status of the primary data is from
tumor
patient records.
All data was
verified by
patient records
Found in the
Tumor Registry
and patient
records. Most
Progesterone
receptor status of the data was from
patient records.
primary tumor
All data was
verified by
patient records
Found in the
Tumor Registry
and patient
records. Most
HER2 Status of the
data was from
primary tumor
patient records.
All data was
verified by
patient records

Comment

Age at the time of
recurrence.
Calculated from age
at primary diagnosis
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Measured in days

Used to determine
phenotype and
concordance. Not
used in any
analysis as an
individual variable

Used to determine
phenotype and
concordance. Not
used in any
analysis as an
individual variable

Used to determine
phenotype and
concordance. Not
used in any
analysis as an
individual variable

Table 24. List of Variables Utilized, Continued

Variable
Name

Description

SSS

Documents the order
of systematic therapy
and surgery

Hormone

Chemo

Rad

Herceptin

Grade
Size

nPos

Source

Found in Tumor
Registry. Not
verified in patient
records
Did the patient
Based on the
receive hormone
review of several
therapy for the
fields in the
primary tumor
Tumor Registry
Did the patient
Based on the
receive
review of several
chemotherapy for the fields in the
primary tumor
Tumor Registry
Did the patient
Based on the
receive radiation
review of several
therapy for the
fields in the
primary tumor
Tumor Registry
Did the patient
Based on the
receive Herceptin
review of several
therapy for the
fields in the
primary tumor
Tumor Registry
Tumor Registry
Primary tumor grade
coded field
Tumor Registry
Primary tumor size
field
Number of positive
lymph nodes
Tumor Registry
associated with the
field
primary tumor

AJCC Simple

AJCC cancer stage
coding (pg.
47)("Breast Cancer,"
2015)

Tumor Registry
field

Type Chemo

The type of
chemotherapy
provided for adjuvant
therapy for the
primary tumor

Created from a
Tumor Registry
text field
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Comment
Coded as Before,
After, Both, None
or Missing

Yes, No or Missing

Yes, No or Missing

Yes, No or Missing

Yes, No or Missing

Coded

AJCC stage
without the letter
designation,
utilizing just
0,1,2,3,4

Table 24. List of Variables Utilized, Continued

Variable
Name
Age DX
dDate

Description
Patient age at
diagnosis of primary
tumor
Date of diagnosis of
primary tumor

Source

Comment

Tumor Registry
field

Used to calculate
other variables

Tumor Registry
field

Used to calculate
other variables

Appendix 8: Information Only Variables

Table 25. Information Variables

Variable
Name
Gen Stage
ID Code
Random

SSF 15

SSF 16
Rad Start
Rad End
Dose

Chemo Text

Description

Source

Comment

General staging of
the primary disease
Used to link patient
ID to data records

Tumor Registry
field

Used to validate
other variables
Patient ID kept in
a separate file
Used to randomly
assign codes so no
pattern is present
Used to help
validate
administration of
Herceptin for the
primary diagnosis
Used to validate
other variables
Used to validate
other variables
Used to validate
other variables
Used to validate
other variables
Used to validate
other variables

Used to link patient
ID to data records

HER2 status
summary code

Created by me
Created by me
Tumor Registry
field

Phenotype summary Tumor
of the primary tumor field
Radiation start date Tumor
for primary tumor
field
Radiation end date
Tumor
for primary tumor
field
Radiation dose for
Tumor
primary tumor
field
Text field describing Tumor
the chemotherapy
field
treatment for the
primary tumor
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Registry
Registry
Registry
Registry
Registry

Table 25. Information Variables, Continued

Variable
Name
Horm Start
Date
RSN No
Horm
Recur Type
2nd Recur
2nd Type
Order
Prim
Mng
Fol

Description

Source

Comment

Hormone treatment
start date for
primary tumor
Text field for reason
hormone therapy
was not performed
Type of recurrence
by location
Date of a 2nd
recurrence
Type of 2nd
recurrence
Ties record to
original dataset
Primary Surgeon of
record
Managing doctor of
record
Following doctor of
record

Tumor Registry
field

Used to validate
other variables

Tumor Registry
field

Used to validate
other variables

Tumor Registry
field
Tumor Registry
field
Tumor Registry
field

Used to validate
other variables
Used to validate
other variables
Used to validate
other variables
Used for quality
control
Information
purposed only
Information
purposed only
Information
purposed only
Information
purposed only

Med

Oncologist of record

Complete

Used to indicate
when the data
collection on a given
record is complete

Created by me
Tumor
field
Tumor
field
Tumor
field
Tumor
field

Registry
Registry
Registry
Registry

Created by me

125

Appendix 9: Discordant Patient Variables

AGE
DX

6

53

PBC

55.5

9/9/2008

TNBC

M

Chemo

Deceased

Visceral

1.41

7

60

HR+

61.6

5/23/2003

TNBC

P

Endocrine

Deceased

Non

1.43

15

37

PBC

39.1

2/8/2005

HR+

P

Chemo + Targeted
then Endocrine

Deceased

Non

4.44

99

61

HER2+

62.5

6/28/2010

TNBC

P

Therapy

Alive

Non

4.99

188

38

HER2+

41.4

2/21/2011

TNBC

M

Chemo

Alive

Visceral

4.17

233

46

HR+

49.2

7/19/2012

TNBC

P

Endocrine

Alive

Visceral

2.9

259

58

HR+

65.2

12/2/2005

PBC

P

Endocrine

Deceased

Visceral

0.88

312

35

HR+

44

1/12/2002

PBC

P

Chemo then
Endocrine

Deceased

Visceral

4.03

355

56

HR+

56.2

10/23/2012

TNBC

P

Endocrine

Deceased

Non

0.88

399

59

HR+

64.7

1/4/2007

TNBC

P

Endocrine

Alive

Visceral

8.55

439

60

PBC

69.5

4/14/2011

HR+

M

Endocrine

Deceased

Visceral

0.66

535

59

PBC

61.2

10/4/2001

HER+

M

Chemo + Targeted

Deceased

Visceral

0.72

538

47

HR+

51.8

11/7/2014

TNBC

M

Chemo

Deceased

Visceral

0.32

558

53

HR+

56.9

1/5/2004

TNBC

M

No Endocrine

Deceased

Visceral

0.55

pPheno

AGE at
Recur

PRS
(Years)

ID
CODE

Rdate

mPheno

FLD

Table 26. Discordant Patients Variables
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FLTP

Status

Visceral

Appendix 10: Initial Cox Regression Results

Figure 33. Initial Complete Cox Regression
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Appendix 11: Power Tables
Coding descriptions for the power tables:
•

Lambda
o L3.5 for Lambda = 3.5
o L2.0 for Lambda = 2.0
o L5.0 for Lambda = 5.0

•

Binning
o C = Continuous
o B10 = 10 bins
o B5 = 5 bins
o B2 = 2 bins

•

Alpha (Type 1 error)
o .05
o .01

•

Censoring
o C0 = no censoring
o C25 = 25% censoring
o C50 = 50% censoring

•

Sample Size
o n1 = n2 unless otherwise noted
o N70/30 = 70%, 30% split of total N
o N85/15 = 85%, 15% split of total N

•

Hazard Ratios
o 1 = both populations equal, thus type 1 error rate
o 1.25, 1.5, 1.75, 2.0 and 3.0
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Table 27. L3.5 C0 C .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0067 0.0116

0.0249

0.0467 0.0736

0.234

0.006

0.0179

0.0542

0.122

0.0088 0.0448

0.1994

0.4516 0.6989 0.9933

0.007

0.1021

0.4804

0.8282 0.9702

1

0.0086 0.2582

0.854

0.9929

1

1

0.0069 0.7015

0.9997

1

1

1

0.0117 0.9693

1

1

1

1

2

3

0.2256 0.6535

Table 28. L3.5 C0 C .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

0.0342 0.047

1.5

1.75

0.0882

0.1408 0.2016 0.4819

0.0349 0.0744 0.1599

0.2992 0.4566 0.8585

0.0437 0.1439 0.4075

0.6893 0.8752 0.9994

0.0394 0.2584 0.7111

0.9447 0.9946 1

0.0434 0.4881 0.952

0.9989 1

1

0.0436 0.8761 0.9999

1

1

1

0.0511 0.9931 1

1

1

1
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Table 29. L3.5 C0 B10 .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0055 0.0096

0.0213

0.0387 0.0615

0.207

0.0055 0.0173

0.0509

0.1148 0.2165 0.6346

0.0081 0.0435

0.1941

0.441

0.007

0.0993

0.4746

0.8231 0.9689

1

0.0083 0.2538

0.8521

0.9925

1

1

0.0068 0.6997

0.9997

1

1

1

0.0118 0.9681

1

1

1

1

2

3

0.6876 0.9926

Table 30. L3.5 C0 B10 .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.0315 0.0429

0.0808

0.131

0.0334 0.0697

0.1498

0.2899 0.4401 0.8472

0.0433 0.1415

0.4035

0.6843 0.8708 0.9994

0.0383 0.2559

0.7075

0.943

0.9938

1

0.0435 0.4829

0.9503

0.9988

1

1

0.0431 0.8735

0.9999

1

1

1

0.0515 0.9931

1

1

1

1
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0.1918 0.4611

Table 31. L3.5 C0 B5 .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

0.0064

0.008

0.0176

0.0362 0.0545 0.1788

0.0053 0.0137

0.0471

0.1102 0.2004 0.5981

0.0065 0.0414

0.1822

0.4166 0.6609 0.9911

0.0075 0.1044

0.4652

0.8211 0.9651

1

0.0095 0.2542

0.8431

0.9932 0.9997

1

0.0097

0.9996

1

1

1

1

1

1

1

0.708

0.0085 0.9663

1.75

2

3

Table 32. L3.5 C0 B5 .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.028

0.0409

0.0731

0.1255

0.182

0.4404

0.0331 0.0607

0.1526

0.284

0.4262 0.8272

0.036

0.1348

0.3917

0.6644 0.8533 0.9995

0.041

0.2623

0.702

0.9383 0.9926

1

0.0441 0.4854

0.9494

0.9989 0.9999

1

0.0462 0.8738

1

1

1

1

0.0438 0.9928

1

1

1

1
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Table 33. L3.5 C0 B2 .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

0.002

0.003

0.0061

0.0135 0.0183 0.0457

0.0042 0.0115

0.0342

0.0785

0.0053 0.0346

0.1564

0.3537 0.5768 0.9663

0.0066

0.084

0.4038

0.7585 0.9398 0.9997

0.008

0.2243

0.8015

0.986

0.9994

1

0.0075 0.6644

0.9989

1

1

1

1

1

1

1

2

3

0.0087

0.957

1.75

2

0.135

3

0.3964

Table 34. L3.5 C0 B2 .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.018

0.028

0.0489

0.083

0.0253 0.0513

0.1182

0.2218 0.3333

0.035

0.1145

0.3502

0.6027 0.8041 0.9947

0.0367 0.2317

0.6534

0.9081 0.9842

1

0.0401 0.4556

0.9289

0.9977

1

1

0.0436 0.8499

0.9999

1

1

1

0.0469 0.9909

1

1

1

1
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0.1141 0.2697
0.689

Table 35. L2.0 C0 C .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.0072

0.013

0.0283

0.049

0.0779 0.2406

0.0077

0.021

0.0645

0.14

0.2358 0.6713

0.0087 0.0558

0.2339

0.5107 0.7465 0.9958

0.0067 0.1346

0.5486

0.8876 0.9814

1

0.0089 0.3163

0.9012

0.9981

1

1

0.7845

1

1

1

1

0.0097 0.9851

1

1

1

1

0.01

2

3

Table 36. L2.0 C0 C .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0364 0.0549

0.0952

0.1556

0.224

0.5013

0.036

0.0804

0.1829

0.3243 0.4825 0.8694

0.0408 0.1655

0.4552

0.7447 0.9063

0.999

0.0415 0.3103

0.7702

0.9693 0.9965

1

0.0471 0.5577

0.971

0.9998

1

1

0.0504 0.9217

1

1

1

1

0.0465 0.9972

1

1

1

1
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Table 37. L5.0 C0 C .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.5

1.75

2

3

0.0051 0.0107

0.023

0.0423

0.069

0.2288

0.0066 0.0159

0.0499

0.1063 0.1922 0.6151

0.0058 0.0399

0.1634

0.3818 0.6166 0.9869

0.0073 0.0867

0.4059

0.7686 0.9438

1

0.009

0.2175

0.7875

0.9865 0.9998

1

0.0096 0.6188

0.9982

1

1

1

1

1

1

1

2

3

0.01

1.25

0.9354

Table 38. L5.0 C0 C .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.0287 0.0452

0.0786

0.1301 0.1913 0.4714

0.0333 0.0634

0.1464

0.2635 0.3946 0.8225

0.0387 0.1239

0.3479

0.6206 0.8232 0.9979

0.0376 0.2221

0.644

0.9069 0.9874

1

0.0468 0.4232

0.9242

0.997

1

1

0.0456 0.8189

0.9999

1

1

1

1

1

1

1

0.0475

0.981
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Table 39. L3.5 C25 C .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0067 0.0078

0.0162

0.0338 0.0516 0.1437

0.0063 0.0151

0.0387

0.0871 0.1492 0.4595

0.0081 0.0329

0.1409

0.3163

0.514

0.9459

0.0065 0.0779

0.3364

0.6755

0.893

0.9998

0.0077 0.1781

0.7157

0.9625

0.998

1

0.0088 0.5412

0.9936

1

1

1

0.0107 0.8896

1

1

1

1

2

3

Table 40. L3.5 C25 C .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.0282 0.0388

0.0656

0.1069 0.1521 0.3431

0.0313 0.0624

0.1238

0.2261 0.3323 0.7033

0.0405 0.1115

0.3085

0.5509 0.7452 0.9897

0.0404 0.2048

0.5733

0.8605 0.9667

1

0.041

0.3816

0.8762

0.991

0.9999

1

0.0454 0.7639

0.999

1

1

1

0.0469 0.9651

1

1

1

1
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Table 41. L3.5 C25 B10 .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0053 0.0061

0.0125

0.0264 0.0415 0.1113

0.0056 0.0133

0.0349

0.0766 0.1274

0.0078 0.0297

0.1293

0.2869 0.4769 0.9226

0.0071 0.0729

0.3158

0.6415 0.8693 0.9996

0.0077 0.1676

0.6864

0.95

0.9967

1

0.0083 0.5156

0.9896

1

1

1

0.0104 0.8722

1

1

1

1

2

3

0.402

Table 42. L3.5 C25 B10 .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.0262 0.0338

0.0584

0.0939 0.1356 0.2978

0.0287 0.0566

0.115

0.2096 0.3111

0.0391 0.1071

0.2884

0.5243 0.7163 0.9809

0.0411 0.1956

0.5506

0.8398 0.9578 0.9999

0.0396 0.3636

0.8603

0.9871 0.9996

0.0459 0.7451

0.9983

1

1

1

0.0475 0.9579

1

1

1

1
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0.655

1

Table 43. L3.5 C50 C .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0047 0.0084

0.0122

0.0193 0.0283 0.0737

0.006

0.0106

0.0258

0.0526 0.0823 0.2521

0.0075 0.0237

0.081

0.1744 0.3146 0.7703

0.0071 0.0473

0.1935

0.4579 0.6767 0.9879

0.0086 0.1112

0.4814

0.8258 0.9645

1

0.0091 0.3512

0.9328

0.9995

1

1

0.0078 0.6991

0.9993

1

1

1

2

3

Table 44. L3.5 C50 C .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.0277 0.0361

0.0512

0.0738 0.0966 0.2133

0.029

0.0482

0.0872

0.1497 0.2081 0.4711

0.0348 0.0856

0.209

0.3738

0.0396 0.1429

0.4006

0.6915 0.8648 0.9981

0.0448

0.269

0.7135

0.9439 0.9926

0.0444 0.5867

0.9801

1

1

1

0.0438 0.8722

0.9999

1

1

1
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0.539

0.9059

1

Table 45. L3.5 C50 B10 .01

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

2

3

0.0024 0.0048

0.0078

0.0113 0.0191 0.0505

0.0044 0.0082

0.0192

0.0426 0.0654 0.1991

0.0061 0.0213

0.0697

0.1483 0.2687 0.6885

0.007

0.0412

0.1711

0.407

0.0083 0.0978

0.4331

0.7786 0.9443

1

0.0091 0.3176

0.9044

0.9974

1

1

0.0075 0.6525

0.9985

1

1

1

2

3

0.6147 0.9725

Table 46. L3.5 C50 B10 .05

Hazard Ratio
n1=n2
10
20
50
100
200
500
1000

1

1.25

1.5

1.75

0.0187 0.0272

0.0393

0.0575 0.0792 0.1637

0.0255 0.0411

0.0767

0.1304 0.1812 0.4133

0.0336 0.0786

0.1884

0.3398 0.4903 0.8686

0.0367 0.1318

0.3665

0.6438 0.8232 0.9936

0.0436 0.2477

0.67

0.0435 0.5521
0.0435 0.8408

0.9203 0.9856

1

0.9706

0.9998

1

1

0.9999

1

1

1
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Table 47. L3.5 C0 C N70/30 .01

Hazard Ratio
n1,n2
6, 14
12, 28
30, 70
60, 140
120, 280
300, 700
600, 1400

1

1.25

1.5

1.75

2

3

0.0088 0.0093

0.0146

0.0267 0.0392 0.1273

0.0062

0.012

0.0379

0.0762 0.1347 0.4558

0.0085 0.0308

0.1257

0.2981 0.5105 0.9483

0.0074 0.0649

0.3289

0.6795 0.8867

1

0.0079 0.1777

0.7042

0.9632 0.9982

1

0.0096 0.5342

0.991

1

1

1

0.0103 0.8946

1

1

1

1

2

3

Table 48. L3.5 C0 C N70/30 .05

Hazard Ratio
n1,n2
6, 14
12, 28
30, 70
60, 140
120, 280
300, 700
600, 1400

1

1.25

1.5

1.75

0.0338 0.0399

0.0628

0.0979 0.1394 0.3377

0.0366 0.0547

0.1227

0.2108

0.323

0.0405 0.1098

0.3051

0.541

0.7449 0.9889

0.0401 0.1983

0.5684

0.8608 0.9653

1

0.0402

0.379

0.878

0.9923 0.9999

1

0.0455

0.763

0.999

1

1

1

0.0467

0.969

1

1

1

1
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0.713

Table 49. L3.5 C0 C N85/15 .01

Hazard Ratio
n1,n2
3, 17
6, 34
15, 85
30, 170
60, 340
150, 850
300, 1700

1

1.25

1.5

1.75

2

3

0.0134 0.0031

0.0029

0.0009

0.001

0.0004

0.0098 0.0074

0.0129

0.0255 0.0483 0.1861

0.0078 0.0132

0.0544

0.1332

0.0088 0.0322

0.1535

0.3732 0.6184 0.9848

0.0084 0.0829

0.4055

0.7743 0.9474

1

0.0076 0.3005

0.9001

0.998

0.9999

1

0.0094 0.6544

0.9985

1

1

1

2

3

0.249

0.7401

Table 50. L3.5 C0 C N85/15 .05

Hazard Ratio
n1,n2
3, 17
6, 34
15, 85
30, 170
60, 340
150, 850
300, 1700

1

1.25

1.5

0.035

0.031

0.0358

0.0486 0.0641 0.1487

0.0377 0.0387

0.0628

0.1097 0.1666 0.4378

0.0374 0.0622

0.1773

0.33

0.0439 0.1194

0.3555

0.6332

0.0392

0.231

0.6571

0.9212 0.9858

1

0.0423 0.5445

0.9714

0.9998

1

1

0.0479

0.9999

1

1

1

0.843
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1.75

0.5009 0.9019
0.825

0.9972

Appendix 12: Simulation Definitions
Key words and concepts utilized in the simulation analysis are defined below:
•

Censoring – A statistical term that describes that fact that not all subjects
in a survival analysis can/are observed until the event (death) occurs. The
subject may be alive at the end of the study or may be lost to observation
for various reasons (Lee & Wang, 2013, pp. 2-5).

•

Kaplan-Meier (KM) – A method of survival analysis created by Kaplan and
Meier in 1958 that utilizes survival data that has censoring (Lee & Wang,
2013, pp. 68-92).

•

Hazard Rate (Failure Rate) – The rate of failure (death) per a given unit of
time (p. 10).

•

Exponential Distribution – A common statistical distribution used in
survival analysis with a constant failure rate (pp. 133–138).

•

Lambda (λ) – The parameter of an exponential distribution where the
mean time to failure (death) is λ.

•

Survival Curve – A graphical curve with percent survival on the Y-axis and
time on the x-axis showing the percent of subjects still alive at a given
point in time (pp. 8-11).

•

Log Rank – A semi-parametric statistical test used to evaluate the
difference between two or more KM survival curves (pp. 112–113).

•

Hazard Ratio (HR) – The ratio of two hazard functions. The ratio indicates
the difference in the instantaneous risk of death between two groups. A
HR of 2 would mean that one group has twice the risk of dying at any
point in time than another group (pp. 282–284).
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•

Proportional Hazards – For the purposes of this dissertation, all analyses
assume proportional hazards, that is, the HR is constant over time (pp.
282–284).

•

Sample Proportions – The proportion of the total sample N = n1 + n2,
that are in each group in an analysis (only two groups were considered in
this analysis). For n1 = n2, the proportions are 50% and 50%.

•

Delta – The hypothesized difference in the metric of interest between
experimental groups that is of interest to the investigator. In the case of
survival analysis the hazard ratio (HR) was used. For example, the
experimenter may wish to statistically detect a difference between two
groups of HR = 1.4 (Sharpe, Veaux, & Vellman, 2010, pp. 289-301).

•

False Positive (Type 1 Error) – The probability that a statistical test will
indicate a difference between groups (two in this case) on the metric of
interest when in fact there is no difference. A priori, this risk is set by the
experimenter and is commonly called alpha. A risk of .05 or 5% is a
common risk taken by practitioners (Sharpe et al., 2010, pp. 289-301).

•

P-value – After a statistical analysis is performed, this is the a posteriori
probability of getting the observed result assuming the null hypothesis is
true. Commonly reported to allow each person assessing a statistical
analysis to apply their own type 1 risk (pp. 289-301).

•

False Negative (Type 2 Error) – The probability that a statistical test will
indicate there is not a difference between two groups when in fact there
is. This risk is called beta. A priori, beta can be controlled by the
experimenter and is impacted by the Delta chosen. A typical type 2 risk is
10% (pp. 289–301).
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Power – Mathematically this number is 1 – beta. The interpretation is that power
is the probability of discovering the desired Delta given the parameters of the
experiment (pp. 289-301).

Appendix 13: Table of MATLAB Programs
Table 51. MATLAB Programs Descriptions

Program

Generate_Data_v3_2p1p2
Generate_Data_v3_2Bin

Compute_log_rank_v2

Power_from_pval

Compute_ndeaths
ndeaths_vs_pval
kmplot

logrank

Description
Exponential random variables generated for two
populations of various sample sizes and hazard
ratios for a given lambda, censor rate and sample
size ratio. Lambda, censor rate and sample size
ratio are manually changed for each run. Bin size
can be changed as well. The code is found in
Appendix 14.
Bin size can be changed as well. Appendix 15.
This code calls a MATLAB M-file (Log Rank) routine
to calculate the p-value for the log rank test
comparing two groups. The p-values are stored in
output files for each sample size/hazard ratio
combination. Appendix 16.
An output table is create for alpha = .01 and alpha
= .05 from the p-values for each combination of
sample size and hazard ratio. See Appendix 17.
For each run of the simulation and each
combination of variables, the number of actual
“deaths” in the simulation is recorded. This data is
used to correlate with various input variables. See
Appendix 18.
This code combines the “deaths” with p-values and
other input variables for analysis. See Appendix 19.
This is a MATLAB provided file that plots KM curves.
See Appendix 20 for the code.
This is a MATLAB provided file that calculates Log
Rank statistics for comparing two survival curves.
See Appendix 21 for the code description.
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Appendix 14: MATLAB Program 1

% Copyright 2015, Tyler J. Massaro, all rights reserved.
% Date: 9 June 2015
%
% Generating exponential random survival data.
clc;
clear all;
close all;

% Allocate storage
N = [10 20 50 100 200 500 1000]; no_N = length(N);
p1=.30; p2=.70;% Create unequal sample size 70/30 or 85/15 split
p = 0.05;
lamda = 3.5; %simlilar to p = .05
censor_rate = 0.00;
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta);
ntrials = 10000;

% Create baseline survival data (exponential)
for i = 1:no_N
NN = 2*p1*N(i);
SURV = exprnd(lamda, NN, ntrials);%changed from 3 to lamda
X = (12*SURV);
binSURV = X;
binSURV(X<=6) = 6;
binSURV(X>6 & X<=12)= 12;
binSURV(X>12 & X<=18)= 18;
binSURV(X>18 & X<=24)= 24;
binSURV(X>24 & X<=30)= 30;
binSURV(X>30 & X<=36)= 36;
binSURV(X>36 & X<=42)= 42;
binSURV(X>42 & X<=48)= 48;
binSURV(X>48 & X<=54)= 54;
binSURV(X>54 )= 60;
Y = rand(NN, ntrials);
% Fixing the CENS data
CENS = double(Y < censor_rate);
CENS(SURV > 5) = 1;
% Store information
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NN = N(i);
csvwrite(['EXP_SURV_N_is_' num2str(NN) '.csv'], SURV);
csvwrite(['EXP_BIN_SURV_N_is_' num2str(NN) '.csv'], binSURV);
csvwrite(['EXP_CENS_N_is_' num2str(NN) '.csv'], CENS);
assignin('base', ['EXP_SURV_N_is_' num2str(NN)], SURV);
assignin('base', ['EXP_BIN_SURV_N_is_' num2str(NN)], binSURV);
assignin('base', ['EXP_CENS_N_is_' num2str(NN)], CENS);
end

% Create new data (exponential)
for i = 1:no_N
NN = 2*p2*N(i);
for d = 1:no_delta
dd = delta(d);
SURV = exprnd(lamda/dd, NN, ntrials);%changed from 3 to lamda
X = (12*SURV);
binSURV = X;
binSURV(X<=6) = 6;
binSURV(X>6 & X<=12)= 12;
binSURV(X>12 & X<=18)= 18;
binSURV(X>18 & X<=24)= 24;
binSURV(X>24 & X<=30)= 30;
binSURV(X>30 & X<=36)= 36;
binSURV(X>36 & X<=42)= 42;
binSURV(X>42 & X<=48)= 48;
binSURV(X>48 & X<=54)= 54;
binSURV(X>54 )= 60;
Y = rand(NN, ntrials);
% Fixing the CENS data
CENS = double(Y < censor_rate);
CENS(SURV > 5) = 1;
% Store information
NN = N(i);
csvwrite(['EXP_SURV_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv'], SURV);
csvwrite(['EXP_BIN_SURV_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv'], binSURV);
csvwrite(['EXP_CENS_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv'], CENS);
assignin('base', ['EXP_SURV_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd)], SURV);
assignin('base', ['EXP_BIN_SURV_N_is_' num2str(NN) ...

145

'_d_is_' num2str(100*dd)], binSURV);
assignin('base', ['EXP_CENS_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd)], CENS);
end
end

Appendix 15: MATLAB Program 2

% Copyright 2015, Tyler J. Massaro, all rights reserved.
% Date: 9 June 2015
%
% Generating exponential random survival data.
clc;
clear all;
close all;

% Allocate storage
N = [10 20 50 100 200 500 1000]; no_N = length(N);
p1=.15; p2=.85;% Create unequal sample size 70/30 split
p = 0.05;
lamda = 3.5; %simlilar to p = .05
censor_rate = 0.00;
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta);
ntrials = 10000;

% Create baseline survival data (exponential)
for i = 1:no_N
NN = 2*p1*N(i);
SURV = exprnd(lamda, NN, ntrials);%changed from 3 to lamda
X = (12*SURV);
binSURV = X;
% binSURV(X<=6) = 6;
%binSURV(X>6 & X<=12)= 12;
% binSURV(X<=12)= 12
% binSURV(X>12 & X<=18)= 18;
% binSURV(X>12 & X<=24)= 24;
% binSURV(X>24 & X<=30)= 30;
%binSURV(X>24 & X<=36)= 36;
binSURV(X<=36)= 36;
% binSURV(X>36 & X<=42)= 42;
% binSURV(X>36 & X<=48)= 48;
% binSURV(X>48 & X<=54)= 54;
binSURV(X>36 )= 60;

146

Y = rand(NN, ntrials);
% Fixing the CENS data
CENS = double(Y < censor_rate);
CENS(SURV > 5) = 1;
% Store information
NN = N(i);
csvwrite(['EXP_SURV_N_is_' num2str(NN) '.csv'], SURV);
csvwrite(['EXP_BIN_SURV_N_is_' num2str(NN) '.csv'], binSURV);
csvwrite(['EXP_CENS_N_is_' num2str(NN) '.csv'], CENS);
assignin('base', ['EXP_SURV_N_is_' num2str(NN)], SURV);
assignin('base', ['EXP_BIN_SURV_N_is_' num2str(NN)], binSURV);
assignin('base', ['EXP_CENS_N_is_' num2str(NN)], CENS);
end

% Create new data (exponential)
for i = 1:no_N
NN = 2*p2*N(i);
for d = 1:no_delta
dd = delta(d);
SURV = exprnd(lamda/dd, NN, ntrials);%changed from 3 to lamda
X = (12*SURV);
binSURV = X;
% binSURV(X<=6) = 6;
%binSURV(X>6 & X<=12)= 12;
% binSURV(X<=12)= 12
% binSURV(X>12 & X<=18)= 18;
% binSURV(X>12 & X<=24)= 24;
% binSURV(X>24 & X<=30)= 30;
%binSURV(X>24 & X<=36)= 36;
binSURV(X<=36)= 36;
% binSURV(X>36 & X<=42)= 42;
% binSURV(X>36 & X<=48)= 48;
% binSURV(X>48 & X<=54)= 54;
binSURV(X>36 )= 60;
Y = rand(NN, ntrials);
% Fixing the CENS data
CENS = double(Y < censor_rate);
CENS(SURV > 5) = 1;
% Store information
NN = N(i);
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csvwrite(['EXP_SURV_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv'], SURV);
csvwrite(['EXP_BIN_SURV_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv'], binSURV);
csvwrite(['EXP_CENS_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv'], CENS);
assignin('base', ['EXP_SURV_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd)], SURV);
assignin('base', ['EXP_BIN_SURV_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd)], binSURV);
assignin('base', ['EXP_CENS_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd)], CENS);
end
end

Appendix 16: MATLAB Program 3

% Copyright 2015, Tyler J. Massaro, all rights reserved.
% Date: 9 June 2015
% Compute_log_rank_v2
% Compute log-rank for binned and for continuous survival data. Also,
% storing p-values for later use.
clc;
clear all;
close all;
alpha = 0.05;
N = [ 10 20 50 100 200 500 1000]; no_N = length(N);
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta);
ntrials = 10000;
results_table = zeros(no_N, no_delta);
results_table_bin = zeros(no_N, no_delta);
for n = 1:no_N
NN = N(n);
Sbase = csvread(['EXP_SURV_N_is_' num2str(NN) '.csv']);
Cbase = csvread(['EXP_CENS_N_is_' num2str(NN) '.csv']);
Sbinbase = csvread(['EXP_BIN_SURV_N_is_' num2str(NN) '.csv']);
for d = 1:no_delta
dd = delta(d);
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Sfname = ['EXP_SURV_N_is_' num2str(NN) '_d_is_' ...
num2str(100*dd) '.csv'];
Cfname = ['EXP_CENS_N_is_' num2str(NN) '_d_is_' ...
num2str(100*dd) '.csv'];
Sbinfname = ['EXP_BIN_SURV_N_is_' num2str(NN) '_d_is_' ...
num2str(100*dd) '.csv'];
S = csvread(Sfname);
C = csvread(Cfname);
Sbin = csvread(Sbinfname);
nreject = 0;
nreject_bin = 0;
pvals = zeros(ntrials, 1);
pvals_bin = zeros(ntrials, 1);
for i = 1:ntrials
X = [Sbase(:, i) Cbase(:, i)];
Y = [S(:, i) C(:, i)];
Xbin = [Sbinbase(:, i) Cbase(:, i)];
Ybin = [Sbin(:, i) C(:, i)];
pval = logrank(X, Y);
pval_bin = logrank(Xbin, Ybin);
pvals(i) = pval;
pvals_bin(i) = pval_bin;
if pval < alpha
nreject = nreject + 1;
end
if pval_bin < alpha
nreject_bin = nreject_bin + 1;
end
end
pwr = nreject/ntrials;
results_table(n, d) = pwr;
pwr_bin = nreject_bin/ntrials;
results_table_bin(n, d) = pwr_bin;
csvwrite(['EXP_p_vals_N_is_' num2str(NN) ...
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'_d_is_' num2str(100*dd) '.csv'], pvals);
csvwrite(['EXP_BIN_p_vals_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv'], pvals_bin);
end
end

Appendix 17: MATLAB Program 4

% Copyright 2015, Tyler J. Massaro, all rights reserved.
% Date: 12 June 2015
%
% Powers from p-values
clc;
clear all;
close all;
alpha = [0.01 0.05];
N = [10 20 50 100 200 500 1000]; no_N = length(N);
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta);
ntrials = 10000;
for i = 1:length(alpha)
a = alpha(i);
results_table = zeros(no_N, no_delta);
results_table_bin = zeros(no_N, no_delta);
for j = 1:no_N
NN = N(j);
for d = 1:no_delta
dd = delta(d);
Pbin = csvread(['EXP_BIN_p_vals_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv']);
P = csvread(['EXP_p_vals_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv']);
Xbin = Pbin < a;
X = P < a;
results_table(j, d) = sum(X)/ntrials;
results_table_bin(j, d) = sum(Xbin)/ntrials;
end
end
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assignin('base', ['CONT_alpha_' num2str(100*a)], results_table);
assignin('base', ['BIN_alpha_' num2str(100*a)], results_table_bin);
end

Appendix 18: MATLAB Program 5

% Copyright 2015, Tyler J. Massaro, all rights reserved
% Date: 27 July 2015
% Compute_ndeaths
% Compute the number of deaths based on censored data
clc;
clear all;
close all;
N = [10 20 50 100 200 500 1000]; no_N = length(N);
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta);
for i = 1:no_N
n = N(i);
for j = 1:no_delta
d = delta(j);
X = csvread(['EXP_CENS_N_is_' num2str(n) '_d_is_' ...
num2str(100*d) '.csv']);
ndeaths = n - sum(X);
csvwrite(['ndeaths_N_is_' num2str(n) '_d_is_' ...
num2str(100*d) '.csv'], ndeaths);
end
end

Appendix 19: MATLAB Program 6

% Copyright 2015, Tyler J. Massaro, all rights reserved.
% Date: 27 July 2015
%
% Number of deaths vs p-values
clc;
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clear all;
close all;
alpha = [0.01 0.05];
N = [10 20 50 100 200 500 1000]; no_N = length(N);
delta = [1 1.25 1.5 1.75 2 3]; no_delta = length(delta);
bin_corr_table = zeros(no_N, no_delta);
cont_corr_table = zeros(no_N, no_delta);

% Compute the correlation coefficient between p-val and ndeaths
for j = 1:no_N
NN = N(j);
for d = 1:no_delta
dd = delta(d);
Pbin = csvread(['EXP_BIN_p_vals_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv']);
P = csvread(['EXP_p_vals_N_is_' num2str(NN) ...
'_d_is_' num2str(100*dd) '.csv']);
ndeaths = csvread(['ndeaths_N_is_' num2str(NN) '_d_is_' ...
num2str(100*dd) '.csv']);
rho_bin = corrcoef(Pbin, ndeaths);
rho_cont = corrcoef(P, ndeaths);
bin_corr_table(j, d) = rho_bin(1, 2);
cont_corr_table(j, d) = rho_cont(1, 2);
end
end

% Compute the variation
ndeaths_avg = zeros(no_N, no_delta);
ndeaths_var = zeros(no_N, no_delta);
for j = 1:no_N
NN = N(j);
for d = 1:no_delta
dd = delta(d);
ndeaths = csvread(['ndeaths_N_is_' num2str(NN) '_d_is_' ...
num2str(100*dd) '.csv']);
ndeaths_avg(j, d) = mean(ndeaths);
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ndeaths_var(j, d) = var(ndeaths);
end
end

% Compute the variation by normalizing wrt N
ndeaths_avg_norm = zeros(no_N, no_delta);
ndeaths_var_norm = zeros(no_N, no_delta);
for j = 1:no_N
NN = N(j);
for d = 1:no_delta
dd = delta(d);
ndeaths = csvread(['ndeaths_N_is_' num2str(NN) '_d_is_' ...
num2str(100*dd) '.csv']);
ndeaths_avg_norm(j, d) = mean(ndeaths/NN);
ndeaths_var_norm(j, d) = var(ndeaths/NN);
end
end

Appendix 20: MATLAB Program 7

function varargout=kmplot(varargin)
% KMPLOT Plot the Kaplan-Meier estimation of the survival function
% Survival times are data that measure follow-up time from a defined
% starting point to the occurrence of a given event, for example the %timefrom the beginning to
the end of a remission period or the time %from the diagnosis of a disease to death. Standard
statistical %techniques cannot usually be applied because the underlying %distribution is rarely
Normal
% and the data are often "censored". A survival time is described as
% censored when there is a follow-up time but the event has not yet
% occurred or is not known to have occurred. For example, if remission %time is being studied
and the patient is still in remission at the end %of the study, then that patientï¿½s remission
time would be censored. %If a patient for some reason drops out of a study before the end of
%the study period, then that patientï¿½s follow-up time would also be %considered to be
censored. The survival function S(t) is defined as %the probability of surviving at least to time t.
The graph of S(t) %against t is called the survival curve. The Kaplanï¿½Meier method can % be
used to estimate this curve from the observed survival times
% without the assumption of an
underlying probability distribution.
%
% Syntax: kmplot(x,alpha,censflag)
%
%
Inputs:
%
X (mandatory)- Nx2 data matrix:
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%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%
%

(X:,1) = survival time of the i-th subject
(X:,2) = censored flag
(0 if not censored; 1 if censored)
note that if X is a vector, all the flags of the second column
will be set to 0 (all data are not censored).
ALPHA (optional) - significance level (default 0.05)
CENSFLAG (optional) - Censored Plot flag (default 0). If 0
censored data will be plotted spreaded on the horizontal
segment; if 1 they will be plotted at the given time of censoring.
Outputs:
Kaplan-Meier plot
Example: (+ indicate that patient is censored)
--------------------Patient
Survival
time
--------------------1
7
2
12
3
7+
4
12+
5
11+
6
8
7
9
8
6
9
7+
10
2
---------------------X=[7 0; 12 0; 7 1; 12 1; 11 1; 8 0; 9 0; 6 0; 7 1; 2 0];
Calling on Matlab the function: kmplot(X) the function will plot the
Kaplan-Meier estimation of the survival function
Created by Giuseppe Cardillo
giuseppe.cardillo-edta@poste.it
To cite this file, this would be an appropriate format:Curve
Cardillo G. (2008). KMPLOT: Kaplan-Meier estimation of the survival
function.
http://www.mathworks.com/matlabcentral/fileexchange/22293

%Input Error handling
args=cell(varargin);
nu=numel(args);
if isempty(nu)
error('Warning: Data vectors are required')
elseif nu>3
if nu>4
error('Warning: Max two input data are required')
end
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end
default.values = {[7 0; 12 0; 7 1; 12 1; 11 1; 8 0; 9 0; 6 0; 7 1; 2 0],0.05,0,1};
default.values(1:nu) = args;
[x alpha cflag flag] = deal(default.values{:});
if ~all(isfinite(x(:))) || ~all(isnumeric(x(:)))
error('Warning: all X values must be numeric and finite')
end
if isvector(x)
x(:,2)=0;
else
if ~isequal(size(x,2),2)
error('KMPLOT requires Nx2 matrix data.');
end
if ~all(x(:,2)==0 | x(:,2)==1)
error('Warning: all X(:,2) values must be 0 or 1')
end
end
if nu>1
if isempty(alpha)
alpha=0.05;
else
if ~isscalar(alpha) || ~isnumeric(alpha) || ~isfinite(alpha)
error('Warning: it is required a numeric, finite and scalar ALPHA value.');
end
if alpha <= 0 || alpha >= 1 %check if alpha is between 0 and 1
error('Warning: ALPHA must be comprised between 0 and 1.')
end
end
end
if nu==3
if isempty(cflag)
cflag=0;
else
if ~isscalar(cflag) || ~isnumeric(cflag) || ~isfinite(cflag)
error('Warning: it is required a numeric, finite and scalar CENSFLAG value.');
end
if cflag~=0 && cflag~=1
error('Warning: CENSFLAG value must be 0 or 1')
end
end
end
clear args default nu
%string for LEGEND function
str1=[num2str((1-alpha)*100) '% confidence interval'];
%sort data by survival time
x=sortrows(x,1);
%table of patients observed for each survival time
%the TABULATE function sets up this matrix:
%table1=[time count percent(on total)]
table1=[0 size(x,1) 1; tabulate(x(:,1))];
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%if all observed time are integers remove not observed time added by
%TABULATE function
table1(table1(:,3)==0,:)=[];
%Table of censored data
table12=tabulate(x(x(:,2)==1));
if ~isempty(table12)
% remove not observed time added by TABULATE function
table12(table12(:,3)==0,:)=[];
% setup the vector of the censored data
[cens,loc]=ismember(table1(:,1),table12(:,1)); %find censored data
end
%the percents stored in the the third column are unuseful;
%so, place in the third column how many subjects are still alive at the
%beginning of the i-th interval.
a1=[table1(1,2); -1.*table1(2:end,2)];
table1(:,3)=cumsum(a1); table1(2:end,3)=table1(1:end-1,3);
%number of deaths in the intervals (don't take in account the censored
%data)
if ~isempty(table12)
table1(cens,2)=table1(cens,2)-table12(loc(cens),2);
end
%finally, delete the first row that is now useless
table1(1,:)=[];
t1=[0;table1(:,1)]; %this is the x variable (time);
%this is the y variable (survival function)
T1=[1;cumprod(1-(table1(:,2)./table1(:,3)))];
if flag %if this function was not called by LOGRANK function
%compute the standard error of the survival function
SE=[0;T1(2:end).*sqrt(cumsum(table1(:,2)./(table1(:,3).* ...
(table1(:,3)-table1(:,2)))))];
end
%censored data plotting
if ~isempty(table12)
%if there are censored data after max(t1), add a new cell into the t1,
%T1 and SE arrays
if table12(end,1)>=t1(end,1)
t1(end+1,1)=table12(end,1)+1;
T1(end+1,1)=T1(end,1);
if flag %if this function was not called by LOGRANK function
SE(end+1,1)=SE(end,1);
end
end
if ~cflag
%vectors preallocation
xcg=zeros(1,sum(table12(:,2))); ycg=xcg; J=1;
%for each censored data into the i-th time interval...
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for I=1:size(table12,1)
%compute how many position into the array they must occupy
JJ=J+table12(I,2)-1;
%find the correct time interval in which censored data must be
%placed
A=find(t1<=table12(I,1),1,'last');
B=find(t1>table12(I,1),1,'first');
%equally divide this interval
int=linspace(table12(I,1),t1(B,1),table12(I,2)+2);
%put all in the vectors of the plotting variables
xcg(J:JJ)=int(2:end-1);
ycg(J:JJ)=T1(A);
%update the counter
J=JJ+1;
end
else
xcg=table1(table1(:,2)==0,1);
ycg=T1(table1(:,2)==0);
end
else
if ~flag %if this function was called by LOGRANK function
xcg=[]; ycg=[];
end
end
%compute the hazard rate
c1=T1.*numel(x);
c2=-(diff(log(c1(1:end-1)))./diff(t1(1:end-1)));
lambda=mean(c2(c2~=0));
if flag %if this function was not called by LOGRANK function
%compute the (1-alpha)*100% confidence interval curves
cv=realsqrt(2)*erfcinv(alpha); %critical value
%lower curve (remember that: the lower curve values can't be negative)
lowc=max(0,T1-SE.*cv);
%if the lower curve reaches the 0 earlier than survival %function, trim the data.
if isequal(lowc(end-1:end),[0; 0])
lowcend=find(lowc==0,1,'first');
else
lowcend=length(lowc);
end
%upper curve (remember that the upper curve values can't be >1)
upc=min(1,T1+SE.*cv);
%eventually, correct the data.
if isequal(upc(end),1)
cupend=find(upc<1,1,'last');
upc(cupend:end)=upc(cupend);
end
%compute the median survival time (if exist...)
if isempty(T1(T1==0.5)) %if there is not a point where T=0.5...
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I=find(T1>0.5,1,'last'); %find the first point where T>0.5
J=find(T1<0.5,1,'first'); %find the first point where T<0.5
if isempty(J) %if all points are >0.5...
mt=0; %...there is no median time
else
%compute the median time by linear interpolation.
p=polyfit([t1(I) t1(J)],[T1(I) T1(J)],1);
mt=(0.5-p(2))/p(1);
str2=['Median time ' num2str(mt)];
%string for LEGEND function
end
else
mt=t1(T1==0.5);
str2=['Median time ' num2str(mt)]; %string for LEGEND function
end
%plot all the data
clf
hold on
S2=stairs(t1(1:lowcend),lowc(1:lowcend),'g--');
%lower confidence interval curve
stairs(t1,upc,'g--'); %upper confidence interval curve
S1=stairs(t1,T1,'b'); %Kaplan-Meier survival function
if mt>0 %if exist a median time...
S3=plot([0 mt mt],[0.5 0.5 0],'k:');
end
if ~isempty(table12) %if there are censored data...
S4=plot(xcg,ycg,'r+');
else
S4=[];
end
hold off
%set the axis properly
xmax=max(t1)+1;
axis([0 xmax 0 1.2]);
axis square
%add labels and legend
txt=sprintf('Kaplan-Meier estimate of survival function (hazard rate: %0.4f)\n',lambda);
title(txt,'FontName','Arial','FontSize',14,'FontWeight','Bold');
ylabel('Estimated survival function','FontName','Arial','FontSize',14,'FontWeight','Bold');
xlabel('Time','FontName','Arial','FontSize',14,'FontWeight','Bold');
if mt
if isempty(S4)
legend([S1 S2 S3],'Data',str1,str2)
else
legend([S1 S2 S3 S4],'Data',str1,str2,'Censored')
end
else
if isempty(S4)
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legend([S1 S2],'Data',str1)
else
legend([S1 S2 S4],'Data',str1,'Censored')
end
end
disp('HAZARD RATE IS AN EXPERIMENTAL FUNCTION!!!!')
end
if nargout
varargout(1)={table1}
varargout(2)={table12};
varargout(3)={t1};
varargout(4)={T1};
varargout(5)={xcg};
varargout(6)={ycg};
varargout(7)={lambda};
end

Appendix 21: MATLAB Program 8

function out = logrank(varargin)
% LOGRANK Comparing survival curves of two groups using the log rank %test Comparison of
two survival curves can be done using a statistical
% hypothesis test called the log rank test. It is used to test the null
% hypothesis that there is no difference between the population %survival curves (i.e. the
%probability of an event occurring at any %time point is the same for each population). This
%function use the %Kaplan-Meier procedure to estimate the survival function, so it is
%mandatory to download
% KMPLOT (http://www.mathworks.com/matlabcentral/fileexchange/22293).
%
% Syntax: logrank(x1,x2,alpha,censflag)
%
%
Inputs:
%
X1 and X2 (mandatory)- Nx2 data matrix:
%
(X:,1) = survival time of the i-th subject
%
(X:,2) = censored flag
%
(0 if not censored; 1 if censored)
%
note that if X is a vector, all the flags of the second column
%
will be set to 0 (all data are not censored).
%
ALPHA (optional) - significance level (default 0.05)
%
CENSFLAG (optional) - Censored Plot flag (default 0). If 0
%
censored data will be plotted spreaded on the horizontal
%
segment; if 1 they will be plotted at the given time of
%
censoring.
%
Outputs:
%
Kaplan-Meier plot
%
Log-rank statistics
%
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%
Example:
%
load logrankdata x1 x2
%
logrank(x1,x2)
%
%LOG-RANK TEST FOR KAPLAN-MEIER SURVIVAL FUNCTIONS
%
%---------------------------------------------------------------------%UL
S.E.
z
p-value (2-tailed test)
alpha
%---------------------------------------------------------------------%6.57226
2.80788
2.16258
0.03057
0.050
%---------------------------------------------------------------------%
The survival functions are statistically different
%
%
Created by Giuseppe Cardillo
%
giuseppe.cardillo-edta@poste.it
%
% To cite this file, this would be an appropriate format:
% Cardillo G. (2008). LogRank: Comparing survival curves of two groups
% using the log rank test
% http://www.mathworks.com/matlabcentral/fileexchange/22317
%Input Error handling
args=cell(varargin);
nu=numel(args);
if isempty(nu) || nu<2
error('Warning: Data vectors are required')
elseif nu>4
error('Warning: Max four input data are required')
end
default.values = {[],[],0.05,0};
default.values(1:nu) = args;
[x1 x2 alpha,cflag] = deal(default.values{:});
if ~all(isfinite(x1(:))) || ~all(isnumeric(x1(:))) ...
|| ~all(isfinite(x2(:))) || ~all(isnumeric(x2(:)))
error('Warning: all X1 and X2 values must be numeric and finite')
end
if isvector(x1)
x1(:,2)=0;
else
if ~isequal(size(x1,2),2)
error('LOGRANK requires Nx2 matrix data.');
end
if ~all(x1(:,2)==0 | x1(:,2)==1)
error('Warning: all X1(:,2) values must be 0 or 1')
end
end
if isvector(x2)
x2(:,2)=0;
else
if ~isequal(size(x2,2),2)
error('LOGRANK requires Nx2 matrix data.');
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end
if ~all(x2(:,2)==0 | x2(:,2)==1)
error('Warning: all X2(:,2) values must be 0 or 1')
end
end
if nu>=3
if isempty(alpha)
alpha=0.05;
else
if ~isscalar(alpha) || ~isnumeric(alpha) || ~isfinite(alpha)
error('Warning: it is required a numeric, finite and scalar ALPHA value.');
end
if alpha <= 0 || alpha >= 1 %check if alpha is between 0 and 1
error('Warning: ALPHA must be comprised between 0 and 1.')
end
end
end
if nu==4
if isempty(cflag)
cflag=0;
else
if ~isscalar(cflag) || ~isnumeric(cflag) || ~isfinite(cflag)
error('Warning: it is required a numeric, finite and scalar CENSFLAG value.');
end
if cflag~=0 && cflag~=1
error('Warning: CENSFLAG value must be 0 or 1')
end
end
end
clear args default nu
%recall KMPLOT function to construct tables of data (table1 and table2),
%tables of censored data (table12 and table 22), Kaplan-Meier variables
%(t1, t2, T1 and T2) and Kaplan-Meier graphical data for censored data
%(xcg and ycg).
try
[table1 table12 t1 T1 xcg1 ycg1 lambda1]=kmplot(x1,0.05,cflag,0);
[table2 table22 t2 T2 xcg2 ycg2 lambda2]=kmplot(x2,0.05,cflag,0);
catch ME
disp('Download KMPLOT: http://www.mathworks.com/matlabcentral/fileexchange/22293')
rethrow(ME);
end
%plot both Kaplan-Meier curves
clf
hold on
S1=stairs(t1,T1,'b'); %Kaplan-Meier curve for treatment 1
if ~isempty(table12)
S3=plot(xcg1,ycg1,'k+'); %Censored data for treatment 1
% (if there are)
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else
S3=[];
end
S2=stairs(t2,T2,'r'); %Kaplan-Meier curve for treatment 2
if ~isempty(table22)
S3=plot(xcg2,ycg2,'k+'); %Censored data for treatment 2
%(if there are)
end
hold off
%set the axis properly
xmax=max([t1;t2])+1;
axis([0 xmax 0 1.2]);
axis square
%add labels and legend
title('Kaplan-Meier estimate of survival functions')
ylabel('Estimated survival functions')
xlabel('Time')
if isempty(S3)
legend([S1 S2],'Treatment 1','Treatment 2')
else
legend([S1 S2 S3],'Treatment 1','Treatment 2','Censored')
end
clear S1 S2 S3 xmax xcg1 ycg1 xcg2 ycg2 t1 t2 T1 T2
%Full-blown LOGRANK procedure
%Merge the first columns of Table1 and Table2 (time intervals)
%and pick-up unique values
A=unique([table1(:,1);table2(:,1)]);
table=zeros(length(A),9); %matrix preallocation
%Out in the first column the time intervals
table(:,1)=A;
%Put in the columns 2 and 3 and in the proper rows the deaths and alive
%taken from table1 columns 2 and 3
[~, ia ib]=intersect(table1(:,1),A);
table(ib,2:3)=table1(ia,2:3);
%Put in the columns 4 and 5 and in the proper rows the deaths and alive
%taken from table2 columns 2 and 3
[~, ia ib]=intersect(table2(:,1),A);
table(ib,4:5)=table2(ia,2:3);
%remove the rows where there arent't deaths in both treatments
table((table(:,2)==0 & table(:,4)==0),:)=[];
clear A c ia ib table1 table2
%fill the "pigeon-holes"
c=find(table(:,3)==0); %find the "pigeon-holes" of treatment 1
for I=1:length(c)
if c(I)~=1
%find the first interval time before the hole where there is almost 1
%death
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J=find(table(1:c(I)-1,3)>0,1,'last');
table(c(I),3)=table(J,3)-table(J,2);
if ~isempty(table12)
%find eventually censored data
K=find((table12(:,1)<table(c(I),1) & table12(:,1)>=table(J,1)),1,'last');
%Put in the hole how many subject were alive before the interval time
%of the hole
if ~isempty(K)
table(c(I),3)=table(c(I),3)-sum(table12(K,2));
end
end
else
table(1,3)=length(x1);
end
end
%Do the same for tratment 2
c=find(table(:,5)==0);
for I=1:length(c)
if c(I)~=1
J=find(table(1:c(I)-1,5)>0,1,'last');
table(c(I),5)=table(J,5)-table(J,4);
if ~isempty(table22)
K=find((table22(:,1)<table(c(I),1) & table22(:,1)>=table(J,1)),1,'last');
if ~isempty(K)
table(c(I),5)=table(c(I),5)-sum(table22(K,2));
end
end
else
table(1,5)=length(x2);
end
end
clear c I J K table12 table22
%Fill the table and compute the statistic variable
%Compute the total deaths and alive before the i-th time interval
table(:,6:7)=[sum(table(:,[2 4]),2) sum(table(:,[3 5]),2)];
%Compute the difference between observed deaths for treatment 1 and
%expected deaths in the hyphthesis that the treatments are similar
table(:,8)=table(:,2)-table(:,3).*table(:,6)./table(:,7);
%Log-rank statistic is the sum of column 8 values
J=sum(table(:,8)); UL=abs(J);
%Compute the contribute to the standard error
table(:,9)=prod(table(:,[3 5 6]),2).*(table(:,7)-table(:,6)) ...
./(table(:,7).^2.*(table(:,7)-ones(size(table,1),1)));
%find if there is some NaN (i.e. 0/0)
loc=isnan(table(:,9));
if any(loc)
table(loc,9)=0;
end
V=sum(table(:,9)); SUL=sqrt(V); %Compute the totale standard error
K=J/V; HR=exp(K); HRci=[exp(K-1.96/SUL) exp(K+1.96/SUL)];
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z=abs((UL-0.5)/SUL); %normalized UL with Yates'es correction
p=2*(1-0.5*erfc(-z/realsqrt(2))); %p-value
%display results
% disp('LOG-RANK TEST FOR KAPLAN-MEIER SURVIVAL FUNCTIONS')
% disp(' ')
% tr=repmat('-',1,110);
% disp(tr)
% disp('HAZARD RATE IS AN EXPERIMENTAL FUNCTION!!!!')
% fprintf('Treatment 1: Hazard rate: %0.4f\n',lambda1)
% fprintf('Treatment 2: Hazard rate: %0.4f\n',lambda2)
% fprintf('\n')
% fprintf('Mantel-Haenszel Hazard ratio: %0.4f\n',HR)
% fprintf('95%% confidence interval: %0.4f - %0.4f\n',HRci)
% disp(tr)
% fprintf('UL\t\t\tS.E.\t\tz\t\tp-value (2-tailed test)\t\talpha\n')
% disp(tr)
% %fprintf('%0.5f\t\t\t%0.5f\t\t%0.5f\t\t%0.5f\t\t\t\t%0.3f\n',UL,SUL,z,p%,%alpha)
% disp(tr)
% if p<alpha
%
fprintf('\t\tThe survival functions are statistically %different\n')
% else
%
fprintf('\t\tThe survival functions are not statistically %different\n')
% end
out = p;

164

VITA

Allen Pannell was born and raised in Knoxville Tennessee. He has three
wonderful children, Melissa, Nicholas and Jessica. He received his B.S. and M.S in
Statistics from the University of Tennessee in 1982 and 1984. His first job was as
a staff statistician at Martin Marietta Energy Systems in Oak Ridge Tennessee.
Allen was then hired by his former professors at UT as a consultant for
Tennessee Associates International (TAI). Allen performed many roles at TAI,
including account manager for major projects as President of the North American
Operations. He led various projects saving clients millions of dollars. Allen
transitioned to a faculty member in the Graduate and Executive Education (GEE)
department at the University of Tennessee, where he was responsible for
successfully leading consulting projects for clients, teaching and certifying Black
Belts, instructing executive MBA candidates in statistical methods for business
decision making and developing Analytics curriculum and programs. Today, Allen
is the Director of Business Analytics at Lincoln Memorial University (LMU). His
role as director and professor is to develop and deliver a Master of Science in
Business Analytics program for the LMU Business School.

165

